Podcasts about Princess Margaret Hospital

This is a personal post and my first post with a request. My wife, life partner and business partner, Ann Hetram, passed away unexpectedly from cancer 2 months ago.  She received excellent care at Princess Margaret Hospital, which is the best cancer hospital in Canada. In her honour, I am co-captain of a team in the Journey to Conquer Cancer walk to support research at Princess Margaret Hospital.  My team is the Harbour Square Team for my condo building. The walk is on Sunday, June 15 at 9 AM. It starts at the University of Toronto, Varsity Stadium, 299 Bloor Street West, Toronto. Donations support breakthrough research, supporting over 1,600 researchers and scientists working on innovative projects, such as early detection methods, personalized cancer treatments, and immunotherapy advancements. Ann's cancer was classified as an “unknown tumor”. She received a personalized cancer treatment including immunotherapy. I'm hopeful that with your support, research will advance to help others facing rare cancers like hers. Whether you walk with us, join virtually, or donate — every step and every dollar counts. Thank you, Ed  

'Darren has reached deeply into the very bottom of toilet humour.' 'iiieeeooo.' Humankind has one more chance, a second-last chance, to survive. We are in a lot of trouble if these zany characters are our last hope. Prison Planet accommodates the American crew, safely landing with all dubious passengers intact. An evil warden assumes the role of dictator for the planet's lifers. Crew 7 must escape the clutches of the warden and his hench . . . men/women/other. But who are the real criminals? The House of FILTH. Some still dealing with their own afflictions, the ex-psychiatric patients stumble upon an oasis on a new planet. The 'most powerful organisation in the universe' does not take kindly to strangers. In another world, on the isolated island of Retro-Tech, who or what is the unknown entity that has seized control? Climb aboard the realm-hopping transport with Arros Sole to get to the bottom of it. Born Darren Edward Watling, Subiaco, Western Australia, 1966. Darren excelled in English, maintaining ‘A's, throughout his schooling and wrote a play, ‘Laughing Gas', for his school at the age of 10. Credited with a few small, published articles, Darren found inspiration and reward, arriving at his latest piece, ‘2nd Last Chance'. He completed an apprenticeship, as a fitter, at Princess Margaret Hospital, while continuing his passion for short story writing. Travelling Australia for three years on a private bus gave Darren a beginning to the experiences and continued, humorous outlook he has on life. Darren approached Jill Stubbs Mills and asked for her blessing to take her short story, ‘Deception', and rewrite it into a novel. (The feedback from Fremantle Press about her story was exceptional). Jill agreed to her son's request. Sadly, Jill now suffers with dementia, but, laughably, keeps her sense of humour. Various forms of employment, including a movie extra, a welder on a crocodile farm, a drummer for a touring band and currently a roof plumber, gave Darren considerable, ‘fuel', for a comedic novel. Darren has had several passions over the past 50 odd years while walking this Earth. Drums, Karate, Tennis and continuing today- comedic writing. You can learn more about Darren E. Watling and his books on Facebook at https://www.facebook.com/darren.watling.37/ and Instagram at  https://www.instagram.com/darren.e.watling/ TOPICS OF CONVERSATION Humor and Satire: Using comedy to critique society and shape characters. Character Inspirations: Creating exaggerated characters with real-world influences. Worldbuilding: Crafting absurd settings like Prison Planet and House of Filth. Writing Process: From adapting a short story to surprising plot twists. Audience and Reception: Targeting older readers and reactions to dark humor. What's next for Darren Watling?

Join us for part two of our post-chemotherapy RPLND discussion with Society of Urologic Oncologists (SUO) members Tim Masterson from Indiana University and Rob Hamilton from Princess Margaret Hospital, University of Toronto. --- This podcast was developed in collaboration with: Society of Urologic Oncology https://suonet.org/home.aspx --- SYNPOSIS The conversation covers critical aspects of RPLND, including surgical techniques, preoperative considerations, common complications like chyle leaks, and post-operative care. Both surgeons emphasize the importance of humility, constant learning, and interprofessional collaboration to enhance surgical outcomes. The experts provide valuable insights and detailed discussions meant to guide urologists. --- TIMESTAMPS 00:00 - Introduction 01:16 - General Steps for RPLND Surgery 07:23 - Finding the Ureters 11:53 - Vascular Control 23:26 - Mitigating Chyle Leak 32:32 - Conclusion --- RESOURCES Expert Approaches to Complex PC RPLND Cases Part 1: https://www.backtable.com/shows/urology/podcasts/201/expert-approaches-to-complex-pc-rplnd-cases-part-1 Society of Urologic Oncology: https://suonet.org/home.aspx

Professor Ramesh Balasubramaniam graduated with a BDSc from the University of Western Australia in 2000 and subsequently practiced general dentistry.  In 2006, he completed a certificate and Master of Science degree in Orofacial Pain at the University of Kentucky. While at the University of Kentucky, Ramesh also underwent training in the field of Dental Sleep Medicine.  Ramesh is a Diplomate of the American Board of Orofacial Pain. In addition, Ramesh completed specialist training in Oral Medicine as well as a Fellowship in Interdisciplinary Geriatrics at the University of Pennsylvania in 2008.  13500+ Patients Treated Author and editor of 2 books 60+ Published Articles 13+ years of teaching experience Ramesh has an appointment as a Clinical Associate Professor at the School of Dentistry of the University of Western Australia and is actively involved in teaching and research.  He is president-elect of the Oral Medicine Academy of Australasia.  He also has public appointments at the Oral Health Centre of Western Australia and Princess Margaret Hospital for Children.  His Oral Medicine Specialist practice focuses on Orofacial Pain, Oral Diseases and Disorders, and Dental Sleep Medicine. In this episode of The Savvy Dentist Podcast, Dr. Jesse Green and Professor  Ramesh Balasubramaniam discuss the three big facets of his professional life. His academic life, his dental practice life, and his expanding commercial business product called Periogold.  Ramesh is driven to impact the world, he's driven to improve people's lives, and in this discussion you will hear the passion that drives him to juggle and balance the busy ecosystem of his personal and business life. [02:28] - Ramesh accidentally fell into a dental career … and has never looked back. [10:06] - The early years after graduation allowed Ramesh to get a clear understanding of the direction he wanted to take his dentistry career. [16:26] - The juggle of work commitments is ‘real'... how does Ramesh handle the incredible workload and day-to-day push-and-pull of life and business? [21:09] - The concept of PerioGold and how Ramesh and his team bought it to market. [34:28] - If you are contemplating a career in Academia, or have a product or business concept of your own, Ramesh explains how to juggle your practice and family life and create the space necessary to bring your ambitions to fruition.

35 years of the Toronto Waterfront Marathon and we are joined by Virginia Lee, who is the only woman to have run every Toronto Waterfront Marathon, including this past weekend! Virginia speaks on this week's episode of the AO Running Podcast, spreading her enthusiasm and inspiration for representation of women and asian women specifically in the running community. This year she is running for a cause for the first time through the TCS Charity Challenge, fundraising for Princess Margaret Hospital in honour of her late father who was treated there. Find out more about the TCS Toronto Waterfront Marathon: https://www.torontowaterfrontmarathon.com/ Register to be an Athletics Ontario member: https://athleticsreg.ca/#!/memberships/athletics-ontario-2024-membership

Drs. Vamsi Velcheti and Nathan Pennell discuss key lung cancer abstracts from the 2024 ASCO Annual Meeting, including data from LUMINOSITY and ADAURA, novel therapies in KRASG12C-mutant advanced NSCLC, and the need for effective adjuvant therapies for patients with rare mutations. TRANSCRIPT Dr. Vamsi Velcheti: Hello, I am Dr. Vamsi Velcheti, your guest host for the ASCO Daily News Podcast today. I'm a professor of medicine and director of thoracic medical oncology at Perlmutter Cancer Center at NYU Langone Health. Today, I'm delighted to welcome Dr. Nathan Pennell, the co-director of the Cleveland Clinic Lung Cancer Program and vice chair of clinical research at the Taussig Cancer Center. Dr. Pennell is also the editor-in-chief of the ASCO Educational Book. Dr. Pennell is sharing his valuable insights today on key abstracts in lung cancer that will be presented at the 2024 ASCO Annual Meeting. You'll find our full disclosures in the transcript of the episode.  Nate, it's great to have you here on the podcast. Thank you for being here. Dr. Nathan Pennell: Thanks, Vamsi, for inviting me. I'm always excited for the ASCO Annual Meeting, and we have a tremendous amount of exciting lung cancer abstracts. I know we're not going to discuss all of them on this podcast, but even exciting Plenary presentations coming up.  Dr. Vamsi Velcheti: So, one of the abstracts that caught my attention was Abstract 103, the LUMINOSITY trial, which will be presenting the primary analysis at the meeting. So, there's a lot of buzz and excitement around ADCs. Can you comment on this abstract, Nate, and what are your thoughts on key takeaways from this abstract?  Dr. Nathan Pennell: Absolutely, I agree. This is really an exciting new potential target for lung cancer. So historically, when we think about MET and lung cancer, we think about the MET exon 14 skipping mutations which are present in 3% or 4% of adenocarcinoma patients. And we have approved tyrosine kinase inhibitors, small molecule inhibitors that can be very effective for those. What we're talking about here is actually an antibody drug conjugate or ADC telisotuzumab vedotin, which is targeting the MET protein over expression in non-squamous EGFR wild type advanced non-small cell lung cancer. The LUMINOSITY was a single arm, phase 2 study of teliso, and first of all, I think we have to define the patient population. So, these were MET over expressing non-small cell lung cancer by immunohistochemical staining. So, it included both what they considered MET high expression and MET intermediate expression, both of which had to be 3+ IHC positive on 25% to 50% of cells in the intermediate and 50% or higher in the high expressing group. They were treated with the ADC and had pretty promising results, a response rate of 35% in the MET high group and 23% in the intermediate group. Duration of response at nine months and 7.2 months in those two groups, and the PFS was five and a half and six months. So I would say in a previously treated population, this was relatively promising and potentially defines a completely new and unique subgroup of biomarker defined patients. So, Vamsi, I'm curious, though, if this ends up moving forward to further development, what your thoughts are on adding yet another biomarker in non-small cell lung cancer? Dr. Vamsi Velcheti: Yeah, I think it's certainly exciting. I think for this population, we really don't have a lot of options beyond the second line, and even in the second line, docetaxels are low bar. So,I think having more options for our patients is certainly outcome development. And I think MET IHC is relatively easy to deploy in a clinical setting. I think we already test for MET PD-L1 IHC routinely, and now recently, as you know, HER2 IHC given approval for ADCs, HER2 ADCs there in that space. So, I think from a technical standpoint, I don't see a big barrier in terms of adding an additional IHC marker. And usually, the IHC testing is pretty quick. And I think if you have a therapeutic approval based on IHC positivity, I think certainly from an operational standpoint, it shouldn't be a very complicated issue. Dr. Nathan Pennell: Yeah, I agree. This is cheap. It's something that can be done everywhere in the world. And as you said, in addition to diagnostic IHC, we're already looking at PD-L1, and probably moving towards doing that for HER2. This is really wonderful that we're moving into kind of the era of the ADCs, which is opening up a whole new therapeutic group of options for patients. Dr. Vamsi Velcheti: So, the other abstract that caught my attention was like, the Abstract 8005. This is the molecular residual disease MRD analysis from the ADAURA trial. The ADAURA trial, as you all know, is the trial that led to the FDA approval of adjuvant use of osimertinib in patients with EGFR mutant stage 1B through 3A non-small cell lung cancer. And in this trial, osimertinib demonstrated significant improvements in DFS and OS. And in this particular study, Abstract 8005, the authors looked at the role of MRD in predicting DFS in the study. And after 682 patients who were randomized, 36% of the patients had samples to look at MRD post- surgery. And in the trial the MRD status predicted DFS or event free survival at 36 months with a hazard ratio of 0.23. And the MRD status had a median lead time of 4.7 months across both the arms, both osimertinib and the placebo arm. So, suggesting that MRD could potentially identify high risk subgroups of patients post-surgery to tailor personalized approaches potentially in this population. So, Nate, in your practice, of course, we don't have a clinically validated approach yet to kind of use MRD in this setting, but if we have an option to use an MRD based assay, do you think that would potentially be an opportunity to perhaps escalate or de-escalate adjuvant strategies with TKIs in the adjuvant setting? Do you see value in using MRI assays post- surgery? Dr. Nathan Pennell: Yeah, I think this is a really important study because this is such an important topic around adjuvant targeted treatment. So, of course, ADAURA really changed how we treated people with EGFR mutant lung cancer who underwent surgical resection, because we know that the three years of osimertinib significantly improved disease-free survival and overall survival. But there's still a lot of questions being asked about, is that affordable? Obviously, we're putting a lot of resources into three years of treatment, and not everyone necessarily needs it. There may well be people who are cured with surgery alone and adjuvant chemotherapy. And then what about duration? Is three years enough? Do we need even longer treatment, or do we need shorter treatment? And up to date, we haven't really been able to tell people at risk of recurrence other than the pure odds-based risk based on their stage.   And the assay that was used in the ADAURA study was a personalized tumor informed assay based on the resected tumor. It's unclear to me whether this was just a subgroup of people that had this done or whether they tried to do it in all 600 patients and only, it looks like they were successful in about 32% of people. Maybe about a third were able to successfully have a tumor informed assay. So, the first question is, “Can you use this to help guide who needs treatment or not?” And I think what they showed was only about 4% of people in osimertinib arm in 12% had MRD positive at baseline after surgery. So probably, upfront testing is not really going to be all that helpful at determining who's at high risk and needs to be treated.   Interestingly, of those who were positive, though, most of them, or 80% of them, did go MRD negative on osimertinib. And what I found really interesting is that of those who did have a recurrence, 65% of them did have the MRD test turn positive. And as you mentioned, that was about five months prior to being picked up radiographically, and so you can pick them up sooner. And it also looks like about two thirds of recurrences can be identified with the blood test. So that potentially could identify people who are recurring earlier that might be eligible for a more intensive treatment. The other thing that was really interesting is of those who recurred in the osimertinib arm, 68% of them happened after stopping the osimertinib, suggesting that for the majority of patients, even those not necessarily cured, they seem to have disease control while on the osimertinib, suggesting that maybe a longer duration of treatment for those patients could be helpful. The problem is it still isn't necessarily helpful at identifying who those people are who need the longer duration of treatment. So, definitely an important study. I think it could be useful in practice if this was available clinically, especially at monitoring those after completion of treatment. I think as the sensitivity of these MRD assays gets better, these will become more and more important. Dr. Vamsi Velcheti: I think it's a little bit of a challenge in terms of standardizing these assays, and they're like multiple assays, which are currently commercially available. And I think the field is getting really complicated in terms of how you incorporate different assays and different therapeutics in the adjuvant space, especially if you're kind of looking at de-escalating immunotherapeutic strategies at the adjuvant setting, I think, makes it even more challenging. I think exciting times. We definitely need more thoughtful and better studies to really define the role of MRD in the adjuvant space. So, I guess more to come in this space. Dr. Nathan Pennell: Vamsi, I wanted to ask you about another really interesting Abstract 8011. This is a subgroup of the AEGEAN perioperative study for early-stage resected non-small cell lung cancer. This abstract is specifically looking at baseline N2 lymph node involvement in stage 2A-3B with N2 positive patients in an exploratory subgroup analysis. What are your key takeaways from the study?   Dr. Vamsi Velcheti: I felt this was a very interesting abstract for a couple of reasons. As you know, this is the AEGEAN trial, the phase 3 trial that was reported earlier last year. This is a perioperative study of durvalumab plus new adjuvant chemotherapy versus new adjuvant chemotherapy alone and adjuvant durvalumab plus placebo. The study obviously met its primary endpoint, as we all saw, like the event-free survival. And here in this abstract, the authors present an exploratory subgroup analysis of patients who had N2 lymph node involvement prior to study enrollment. So, in this study, they were focusing on perioperative outcomes. And one of the issues that has come up multiple times, as you know, in a lot of these preoperative studies, is the impact of neoadjuvant chemo immunotherapy on surgery or surgical outcomes. And consistently, across a lot of these trials, including the CheckMate 816, about 20% of patients don't end up making it to surgery. So in that light, I think this study and the findings are very interesting. In this study, they looked at patients who had N2 nodal involvement and of the patients with N2 nodal involvement, the surgical operability or the number of patients who completed surgery was similar in both the groups. So, there was no significant difference between patients who received durva versus chemotherapy and also among patients who had N2 subgroup who had surgery, similar proportions of durvalumab and placebo arms had open versus minimally invasive versus pneumonectomy. So durvalumab didn't have a negative impact on the type of surgery that the patients had at the time of surgery. So overall, the findings were consistent with other trials, perioperative trials that we have seen. So, the surgical outcomes were not negatively impacted by adding immunotherapy in the neoadjuvant perioperative space. So, this is consistent with other trials that we have seen. And also, the other issue, Nate, I'd like to get your opinion on is, across the board, in all the perioperative trials we have seen that about 20% of the patients actually don't end up making it a surgery. And of course, most of these perioperative trials, a lot of these patients are stage 3 patients. And my take on this was that there's probably a little bit of a patient selection issue. We generally tend to err on the side of operability when we have a stage 3 patient discussed in the tumor board, sometimes feel like the patient may downstage and could potentially go to surgery. But even in the real world, in stage 3 operable patients, what proportion of patients do you think don't end up going to surgery? Dr. Nathan Pennell: That is such an important question that I don't think we have the best answer to. You're right. All of these perioperative studies have a relatively high- sort of 20% to 30% of people who enroll on the studies don't necessarily go to surgery. And I don't think that they've done as great a job as they could in all of these trials describing exactly what happens to these patients. So in the real world, obviously not everyone would be fit enough to go to surgery or might progress in the time between when they were diagnosed and the time as planned for surgery. But probably more of them would go to surgery if they weren't getting neoadjuvant treatment, because that would be their initial treatment. The question is, of course, is that the right choice? If someone gets 12 weeks or nine weeks of neoadjuvant treatment and then a restaging scan shows that they've had progression with metastatic disease, are those really the people that would have been optimally treated with surgery upfront, or would they just have had recurrence on their first postoperative scan? So, it's really an important question to answer. I think the bigger one is, is the treatment preventing them through toxicity from going to treatment? And I think the studies have generally felt that few patients are missing out on the option of surgery because of toxicity being caused by the IO. And in the AEGEAN study, for example, in this subgroup, a slightly numerically higher percentage of patients in the durvalumab arm actually underwent surgery compared to those who got neoadjuvant chemo. So, it doesn't seem like we're necessarily harming people with the neoadjuvant treatment. But I know that this is a concern for patients and doctors who are undergoing this approach. Dr. Vamsi Velcheti: Definitely, I think having multiple data sets from perioperative trials, looking at the relative impact of IO on the safety and the nature of the surgery is going to be important, and this is a very important study for that reason. Dr. Nathan Pennell: Can I ask you another thing that I thought really interesting about this particular one is they looked at the difference between those with single station N2 and multi station N2. And I know this is one of those, should we be operating on people who have multi station N2 disease? And the AEGEAN study did include people who had multiple N2 stations where perhaps in the pre-IO era, these would have been treated with definitive chemoradiation and not surgery at all. But the disease-free survival hazard ratio was essentially the same for multi station N2 as it was in the overall population. So, has that changed the way we're approaching these patients in these multidisciplinary discussions? Dr. Vamsi Velcheti: Absolutely, Nate. I think surgical operability is in the eye of the beholder. I think it depends on which surgeon sees the patient or how the discussion goes in the tumor boards, as you know. Certainly, I think with this optionality of having a chemo IO option and potential for downstaging, kind of pushes, at least in our practice, more of these patients who are multistation, who would have otherwise gone down the chemoradiation route are now actually going through neo adjuvant chemo IO and with the hope that they would make it to surgery. So, I think it's an interesting change in paradigm in managing our locally advanced patients. So, I think it's certainly interesting, but I guess to your point, there clearly are some patients who probably should just have chemoradiation upfront, and we may be kind of like delaying that definitive chemoradiation approach for at least a subset of patients. So, at the end of the day, I think it's a lot of clinical decision-making and I think there's going to be a little bit of art to managing these patients and it's going to be really hard to define that population for a clinical trial.  Dr. Nathan Pennell: Yeah, clearly, multidisciplinary discussion, still very important for earliest age non-small cell lung cancer patients. If we move back to metastatic lung cancer, let's talk about Abstract 8510 looking at one of our newer, exciting biomarkers, which are the KRASG12Cmutant non-small cell lung cancer. So this is a study of a second generation KRASG12Cinhibitor, olomorasib, which was combined with pembrolizumab, the anti PD-1 antibody, in patients with advanced KRASG12C mutant non-small cell lung cancer. This is something that has been tried before with first generation G12C inhibitors, with some concerns about how safe it was to do that. So, Vamsi, what did you learn from this abstract? Dr. Vamsi Velcheti: Definitely, I think one of the concerns that we've had in other trials is like the cumulative toxicity of adding checkpoint inhibition to G12C inhibitors, especially the sotorasib CodeBreaK trial, where we see increased rates of grade 3, 4 transaminitis. So, it is encouraging to see that some of the newer agents have less of those issues when it comes to combining the checkpoint inhibition. So especially with KRASG12C, as you know, these are patients who are smokers, and often these are patients who have high PDL-1 could potentially also benefit from immunotherapy. In order for these KRASG12C inhibitors, in order to move these targeted therapy options for these patients to the front line, I do think we need to have substantial comfort in combining the checkpoint inhibitors, which is a standard treatment approach for patients in the frontline setting. I think this is exciting, and I think they're also like, as you know, there are other KRASG12C inhibitors also looking to combine with checkpoint inhibition in the frontline settings. So, we'll have to kind of wait and see how the other agents will perform in the setting. Dr. Nathan Pennell: Yeah, I completely agree. I think this is such an important area to explore specifically because unlike our other targeted oncogenes like EGFR and ALK, we have multiple options for these patients, both immunotherapy and targeted treatments. And if we could think about sequencing them or even combining them and if it could be done safely, I think that would be well worth investigating. There still was significant toxicity in this trial; 30% of people had diarrhea, even at the reduced dose, and there was transaminitis at sort of about 20% or so, although probably at a manageable level. But the response rate was really quite promising. And these are all previously IO and mostly G12C TKI pre-treated patients still had a response rate of 63%. And in those who were naive to IO and TKIs, it was 78% response rate. So, if it could be done safely, I think it's definitely worth pursuing this in further trials. Dr. Vamsi Velcheti: And also, there's some data, preclinical data, like looking at G12C inhibition. And also we have known with MET inhibition for a long time that it could potentially augment immune responses and could be having some synergistic effect with IO. So, we'll have to wait and see, I think. But safety is really the top in mind when it comes to combining these agents with checkpoint inhibitors. So, it's really encouraging to see that some of the newer agents may be more combinable IO. Now moving on to the next abstract, and moving on to, again, the early-stage setting. So, Abstract 8052 from our colleagues in Princess Margaret reported outcomes in early-stage non- small cell lung cancer in patients with rare targetable mutation. This is actually becoming increasingly more relevant because we are seeing at least, like with the ALINA data, with the ALK and EGFR, now with ADAURA, we know that these patients don't benefit with adjuvant immunotherapy, especially some of these rare oncogene living mutations, other than like G12C. So I always struggle with this. When you have early-stage patients, with, let's say, a ROS or a RET, where we just don't have data, and we know that those are poor actors because biologically these are aggressive tumors. So, there's a really odd clinical question to ask in terms of, what is the role of adjuvant immunotherapy? Of course, this trial and this abstract are not really addressing that. But what is your take on this abstract? If you could just summarize the abstract for us. Dr. Nathan Pennell: Sure. Well, I think this is incredibly important, and this is an area near and dear to my own heart. And that is, of course, the whole landscape of how we manage early-stage patients has changed with both ADAURA, because we now have effective treatment in the adjuvant setting for EGFR mutant patients, and now more recently with the ALINA trial for adjuvant alectinib for ALK positive patients now being FDA-approved. So, what that means is we actually have to be testing people at diagnosis even before they would be getting adjuvant treatment, and potentially before even surgery to look for these targets. We need the PD-L1 status, we need EGFR and ALK. And if you're going to be looking at these biomarkers, I think there is a reasonable argument to be made that you should be doing broad testing for all of the targetable oncogenes in these patients. There are some studies suggesting that there's value to this and identifying them for treatment at the time of recurrence. But we also know that these patients are at high risk of recurrence and probably need to be investigated, at least in trials for the adjuvant setting. So, this particular study looked at 201 resected, mostly adenocarcinoma patients, and then they basically sequenced them for all of the targeted oncogenes. And they were quite common, perhaps even more common than you might expect in an advanced population. So, 43% of them had KRASG12C mutations, 13% had EGFR Exon 20 mutation, ERBB2 or HER2 mutations found in 11%, MET mutations in 10%, ALK in 7%, ROS1 in 6%, BRAF in 5%, and RET in 2%. So quite common to find these targetable oncogenes in this particular population, perhaps a somewhat biased population at Princess Margaret Hospital, but very common. And then they looked at the outcomes of these patients without targeted adjuvant treatment. And what they found was there was a very high rate of recurrence. So, relapse-free survival was pretty high in these patients across different stages, and generally their prognosis was worse than the more common KRASG12C patients. Most of these, in particular the HER2 mutant patients, seem to have a significantly worse relapse free survival. Interestingly enough, though, that did not carry over to overall survival. Overall survival was better in those who had targetable oncogenes. And my guess is that that probably had to do with the availability of targeted treatments at the time of recurrence that may have impacted overall survival. But I do think that this particularly highlights the need, the unmet need for effective adjuvant treatment in these patients. And most of them, with the exception of KRAS and perhaps BRAF, perhaps MET unlikely to benefit from adjuvant immunotherapy, as you mentioned. And so, I think we really need to be investing in trials of adjuvant targeted treatments in these populations.  Dr. Vamsi Velcheti: Yeah, this is an area that we really don't have a lot of data. But Nate, a question for you. So tomorrow you have a patient with RET fusion, stage 2, N1 disease. What would you do? Would you offer them an adjuvant RET inhibitor? Dr. Nathan Pennell: I think I would search really hard for a trial to give them access. But if you really want to know what I think, and I'm usually willing to tell people what I think, I think the proof of concept is there. I think we know that in the setting of highly effective and very tolerable adjuvant targeted treatment in the EGFR space with osimertinib, in the ALK space with alectinib, if anything, drugs like selpercatinib and pralsetinib in RET fusion positive lung cancer in the advanced setting are just as well tolerated and easily as effective and long lasting. And so, I think if you did a trial and they are doing trials looking at these drugs in the adjuvant space, almost certainly you're going to see the same really dramatic disease-free survival benefit from these treatments, which, at least in the EGFR space, seems to have translated into an improvement in overall survival. And so if I had a stage II or a resected stage 3, especially a RET fusion positive patient today, I would definitely talk to them about off-label use of a RET inhibitor if I could not find a trial. Now, I understand that there are going to be reimbursement issues and whatnot associated with that, but I think the extrapolation is worth discussing. Dr. Vamsi Velcheti: Yeah, I think it's really challenging because some of these fusions are so rare and it's hard to really do large adjuvant trials for some of these rarer subgroups. Nate, fascinating insights. Our listeners will find links to the abstracts we discussed today in the transcript of the episode. And Nate, I look forward to catching up with you at the Annual Meeting, and again after the meeting for our wrap up podcast to discuss the practice-changing lung cancer abstracts and highlights from the Plenary Session. Thank you so much for joining us and sharing your insights today. Dr. Nathan Pennell: Thanks for inviting me. Vamsi. I look forward to touching base after we get to see all the late-breaking abstracts. Like I said, this is, I think, a year for lung cancer with a lot of exciting data, and I know we'll have a lot to talk about. Dr. Vamsi Velcheti And thank you so much to all our listeners for your time. If you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate and review and subscribe wherever you get your podcast.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers: Dr. Vamsi Velcheti @VamsiVelcheti   Dr. Nathan Pennell @n8pennell   Follow ASCO on social media:   @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn     Disclosures: Dr. Vamsi Velcheti: Honoraria: ITeos Therapeutics Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen, Elevation Oncology, Taiho Oncology, Merus Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline   Dr. Nathan Pennell:   Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron  Research Funding (Inst): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi 

Fire and Emergency New Zealand crews are battling a significant vegetation fire in Christchurch's Port Hills. Early Valley, Worsley Spur, Worsleys Road and Princess Margaret Hospital have been evacuated, with multiple evacuation centres in place. Summit Road is closed between Dyers Pass and Gebbies Pass Roads, and residents in that area need to be ready to evacuate at short notice. Newstalk ZB's Emily Ansell is at the base of the Port Hills, and she says helicopters are on the scene trying to control the blaze. "The fire looks like it's burning up that pine forest just up on the Port Hills, to the right of the park."  LISTEN ABOVESee omnystudio.com/listener for privacy information.

In this podcast episode, Dr. Rami Kotb and Dr. Donna Reece discuss results of the CMRG Isa-CYBORD trial presented at the ASH 2023 meeting, and the implications of the results for Canadian clinical practice.Our Guests:Dr. Rami Kotb is a physician in the Division of Hematology, Department of Medical Oncology & Hematology at CancerCare Manitoba, Winnipeg, MB, CanadaDr Donna Reece is the Director and a Professor of Medicine in the Program for Multiple Myeloma and Related Diseases at the University Health Network. She is also a Professor of Medicine at the University of Toronto and Princess Margaret Hospital in Toronto, ON, CanadaNote: A link to the abstract at ASH can be found here: https://ash.confex.com/ash/2023/webprogram/Paper190168.htmlThis podcast episode was sponsored by Sanofi-Aventis Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Exploring Bermuda's improved pathway for breast cancer care with Dr.Chris Fosker, Medical Director at Bermuda Cancer and Health Centre, shedding light on innovations and patient-centered approaches. Dr Fosker is the Medical Director at Bermuda Cancer and Health Centre, where he oversees the medical care provided to patients across the Centre. He ensures that the centre provides high-quality, evidence-based care to its patients. In addition to his administrative role, Dr Fosker is a practising clinical oncologist who meets with patients and works closely with other healthcare professionals to develop treatment plans, coordinate care, and monitor patient outcomes. Dr Fosker is highly qualified to treat cancer patients with radiation therapy, chemotherapy, molecular therapy, and immunotherapy. Before moving to Bermuda, he worked as a specialist at St James Institute of Oncology in Leeds, which is Europe's largest purpose-built cancer centre. He has completed a Fellowship at Princess Margaret Hospital in Toronto and has published research in a number of clinical areas, as well as in medical education, service development, and health economics. Dr Fosker is also an experienced policy advisor, having worked for the Macmillan Cancer Charity and NHS England as a clinical advisor. He is the recipient of several awards, including the ‘RS Bush Award' for academic excellence fromPrincess Margaret Hospital and the University of Toronto. Dr Fosker received a Bachelor ofScience in Genetics from the University of Leeds. As a member of the senior management team, Dr Fosker provides strategic clinical directionfor the Centre. His extensive experience and expertise in oncology make him an invaluableasset to the team and to the patients who receive care at Bermuda Cancer and HealthCentre.   Sponsor – Lindo's Group of Companies

Canterbury's youth mental health services say they are struggling to meet increasing demand. Over the past decade, the number and complexity of cases those on the frontline are dealing with has ballooned by 121 percent. Te Whatu Ora's district service manager Deborah Selwood admits this demand in growth means only the most severe cases can be seen with any consistency. The physical condition of the current community treatment facility - Princess Margaret Hospital - is only compounding the problem. However, the construction of a new treatment facility - Kahurangi - is nearing completion, with community teams scheduled to move in next year. Deborah Selwood, Te Whatu Ora's Child, Adolescent and Family mental health service manager, joins Kathryn to discuss.

ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. The theme of the 2023 ASCO Annual Meeting was “Partnering With Patients: The Cornerstone of Cancer Care and Research.” From June 2 to 6 in Chicago, Illinois, and online, cancer researchers and clinicians from around the world gathered to discuss the latest cancer research and how to ensure that all people receive the cancer care they need. In the Research Round Up series, members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field presented at the meeting and explain what it means for people with cancer. In today's episode, our guests will discuss new research in symptom tracking and improving health equity in childhood cancer. First, Dr. Fay Hlubocky discusses research on new ways of tracking symptoms in order to improve outcomes in people with cancer. Dr. Hlubocky is a licensed clinical health psychologist with an expertise in psychosocial oncology and a health care ethicist at the University of Chicago. She is also the 2023 Cancer.Net Associate Editor for Psychosocial Oncology. You can view Dr. Hlubocky's disclosures at Cancer.Net. Dr. Hlubocky: Welcome. I'm very glad that you are able to join us today. My name is Dr. Fay Hlubocky. I am honored to serve as the Cancer.Net Associate Editor for Psychosocial Oncology. I'm a clinical health psychologist specializing in psychosocial oncology at the University of Chicago Medicine. Psychosocial oncology centers on addressing the emotional needs of patients, caregivers, and clinicians from clinical research and educational perspectives. I have no conflicts of interest to report today. Today, we will discuss research on quality cancer care that was presented at the 2023 ASCO Annual Meeting. The theme for this year's meeting selected by the 2022-2023 ASCO President, Dr. Eric Winer, required all attendees to critically examine how interactions between clinicians and patients have changed over the years. “Partnering with Patients: The Cornerstone of Cancer Care and Research” centered on the need to observe what has been improved, what has worsened, and what can be achieved to make interactions between clinicians and patients better. The extraordinary quality and psychosocial care research presented at this meeting honored and fulfilled Dr. Winer's theme. For example, one session centered on the use of novel informatics technology to carry out research and care in the cancer clinical setting. This session, entitled, “Implementing Innovation Informatics-based Technologies to Improve Care Delivery and Clinical Research,” illuminated the current research progress of implementation for emerging information technology innovations in cancer care delivery. This session was designed to help oncologists and cancer care team to evaluate whether and how to integrate these innovations into their own clinical context. One outstanding research presentation was by Dr. Monika Krzyzanowska from Toronto's Princess Margaret Hospital called, “Implementing ePROs in the Real World Oncology Practice,” where she emphasized the importance of not only identifying and monitoring patient-reported outcomes or specific symptom burdens such as pain, fatigue, depression, or anxiety in the clinic, but yet they need to be monitored across the patient's treatment course well into survivorship at different time points, including at home. Therefore, there is a need for a standardized approach of identifying symptoms from patients because as Dr. Krzyzanowska said, patients forget to report even distressing symptoms, and clinicians at times are not always prepared to obtain these symptoms from patients. Historically, in the clinic setting and as patients receive treatment in the chemo suite, we have moved from paper and pencil clinical assessments to the use of robust assessments via electronic medical records systems in both the clinic and subsequently while patients are at home. She reported that more than 10 randomized clinical trials examined the benefits of remote monitoring for patients who undergo mostly systematic therapy with consistent improvements in both symptom control and other outcomes, including survival. She provided very robust real-world and life examples of successful implementation of patient symptom monitoring systems. For example, these have shown consistently that there's a need of improvements in symptom control, but improvement with the other outcomes. To date, she reported on several ongoing initiatives, including a large oncology community practice in Arkansas, who reported on their preliminary initial experiences with an assessment platform of 1,000 patients on systemic therapy who reported symptoms on a weekly basis. This team identified a very high recruitment rate of 79% with amazing retention rate at 88% at 6 months, dropping to about 67% at 12 months. Another real-world implementation example she noted is the work by the National Cancer Institute-funded SIMPRO consortium project, where 6 cancer centers evaluate symptom burdens in 2 different clinical scenarios: patients receiving systematic therapy and patients recovering from surgery. Here, patient data and symptoms are collected via an EMR-based E-system to readily respond to patient needs. The preliminary data and a whole host of research presentation centered on SIMPRO at the Annual Meeting showed that it was feasible, but yet a dynamic design is needed to address any operational and technical barriers for optimal implementation. Ideal partnerships between oncologists, cancer teams, patients, administrators, as well as the IT team is needed for optimal implementation as Dr. Krzyzanowska emphasized. Once these interventions are implemented, a study of sustainability of consistent patient reporting with adequate follow-up by team members, such as nursing, is important for long-term practice success. Finally, she reports that the future research of ePROs evaluation will involve novel approaches, such as clinical teams that will need to gather more complex data, including the use of dynamic approaches, such as wearable technologies, machine learning to address barriers and to improve the overall patient experience. In fact, a specific example of this type of research which reported on both the benefits and barriers centering on ePROs trials at the ASCO Annual Meeting included a very large randomized controlled trial by a Danish team led by Dr. Blechingberg Friis to evaluate the effects of remote symptom monitoring of patients with advanced lung cancer completing induction treatment in a Danish setting. Patients were randomized 1-to-1 to a remote symptom monitoring or an intervention arm added to standard care or just a standard care arm alone. Patients in the intervention arm completed an electronic questionnaire from home covering 13 common symptoms related to lung cancer. A severity alarm or threshold was applied to each question where elevated scores were sent to a clinical nurse for intervention. Weekly compliance to symptom monitoring during that first year was 82% with an intention to monitor population. Although remote monitoring did not significantly improve clinical outcomes for all patients with advanced lung cancer in the Danish population, the benefits were identified for a subgroup of patients not receiving maintenance therapy and for those with a prior organizational experience with ePROs monitoring, which may be essential for improving outcomes of symptom monitoring. In summary, as indicated by the researchers and Dr. Krzyzanowska, more research is needed using these novel approaches to determine the best ePROs platforms for the practice setting. Yet these approaches are critical to improve the overall quality of life of patients, especially during treatment, after surgery, and well into long-term survivorship. In summary, patients should be encouraged to discuss symptom burdens from physical to emotional with their oncology team and to use this technology. It was an honor and pleasure to present this research to you today. Thank you for listening to this brief summary of new research and quality care from the 2023 ASCO Annual Meeting. Best wishes. ASCO: Thank you, Dr. Hlubocky. Next, Dr. Daniel Mulrooney discusses new research on improving health equity in children, adolescents, and young adults with cancer. Dr. Mulrooney is an Associate Member in the Division of Cancer Survivorship at St. Jude Children's Research Hospital. He is also the 2023 Cancer.Net Associate Editor for Pediatric Cancers. You can view Dr. Mulrooney's disclosures at Cancer.Net. Dr. Mulrooney: Hello, my name is Dr. Dan Mulrooney from St. Jude Children's Research Hospital. I am the Deputy Director of the After Completion of Therapy Clinic at St. Jude and primarily care for survivors of pediatric cancers. Like previous meetings, the 2023 ASCO Annual Meeting was quite busy and full of research presentations sharing knowledge and advances in cancer treatment and care. Nearly 100 abstracts were presented concerning children with cancer, and these ranged from early studies of new agents to treat relapsed or refractory cancers, some of the most difficult to cure, to molecular profiling of tumors, to late outcome studies characterizing late effects, improved surveillance methods, and potential preventive treatments for adverse effects after cancer therapy. Now, while all of these were particularly exciting to hear and learn about, this year's meeting also had an important focus on addressing equitable cancer care for all children diagnosed with cancer. When a child is ill, it affects the entire family and can be very stressful for all concerned and may especially place a burden on families economically, particularly for those who may live in underserved areas or lack resources when their child is first diagnosed with cancer. Importantly, financial stresses can increase over the course of treatment. And unfortunately, studies have shown that outcomes are inferior for children from low socioeconomic backgrounds compared to those from other, more resource-filled backgrounds, despite the same protocol-driven therapies. Today, I'd like to highlight some of these presentations. Please note, I do not have any relationships to disclose related to any of these studies. A study with the goal of determining the ability to assess social determinants of health in upfront treatment protocols was conducted by the Children's Oncology Group, or COG, a large consortium of pediatric oncology centers that runs national and international trials to advance the treatment of children with cancer. Historically, the COG was only collecting information on race, ethnicity, insurance, and ZIP code. Collecting information on household material hardship may provide information that might be addressed and modified and help improve the treatment of children with cancer. However, before this study, it was not clear if parents would be willing to share this information with their child's treatment team. Investigators asked parents of children newly diagnosed with neuroblastoma and enrolling on the COG study ANBL1531 to complete a survey about where they live, their household income, and their access to stable food, housing, utilities, and transportation, which were called “measures of household material hardship.” Investigators also asked about access to social supports. The surveys were administered with paper and pencil and in the primary language of the participant. 360 of 413 eligible participants, or 87%, opted to complete the survey across 101 different treating sites. 89% of the surveys were completed within 11 days of enrollment. Most participants answered all of the questions. In fact, less than 1% left some questions unanswered. Importantly, nearly one-third of participants reported having household material hardship, of which 55% reported a single insecurity around food, housing, utilities, or transportation. And 45% reported multiple hardships in these domains. These investigators are planning to extend this work and evaluate associations with cancer outcomes in the hopes of better understanding the mechanisms of these disparities and developing interventions to address these issues in future COG studies. This study raised important issues about what can be done to improve or minimize household material hardship for families of children with cancer. In a pilot study conducted by the same study group at the Dana-Farber Cancer Institute and in collaboration with the University of Alabama, investigators studied the feasibility of a randomized intervention providing transportation and groceries to low-income pediatric oncology families. To be eligible, participants had to be less than 18 years of age at diagnosis of cancer and living in a household that screened positive for food, housing, utility, and/or transportation insecurity, the measures of household material hardship, and those who would be receiving at least 4 courses of chemotherapy. Participants were treated at the Dana-Farber Cancer Institute or the University of Alabama between May 2019 and August 2021, and were randomized to receive the intervention called PediCARE, which provided transportation and groceries versus usual care, and this was conducted over a 6-month period. The main outcome was to test the feasibility of the intervention. Would families participate? And the secondary outcome was to assess what proportion of recipients successfully received the intervention and if they found it acceptable. The total of 40 families agreed to participate and be randomized, and none dropped out of the study. All completed surveys at baseline and at the 6-month follow-up period, suggesting that the intervention was feasible, could be successfully delivered, and was acceptable to families. Now another study from the large Childhood Cancer Survivors Study, or CCSS, assessed the association between the expansion of Medicaid under the Affordable Care Act, or ACA, and Medicaid enrollment among childhood cancer survivors. These investigators linked data from over 13,000 5-year childhood cancer survivors to Medicaid insurance data across the years of 2010 to 2016. Survivors were adults, ages 18 to 64 years old, and all had been diagnosed with cancer prior to age 21 years, between the years of 1970 and 1999. The analyses were adjusted for age, sex, race, ethnicity, income, education, and chronic health conditions. The primary aim for these researchers was to determine any Medicaid enrollment for greater than 1 month in the year. They found that Medicaid enrollment rates increased in states that expanded Medicaid coverage from 17.6% pre-expansion to 24% post-expansion, compared to those states that did not expand pre-expansion and 16.9% post-expansion. Adjusting for other factors, the net enrollment increase was 6.6 percentage points. In the expansion states, the increase was greatest among survivors of leukemia and non-Hodgkin's lymphoma. It was also greater among non-Hispanic Black and Hispanic survivors compared to non-Hispanic White survivors and among those with lower household incomes or a high school degree or less. These investigators now plan to look at associations between Medicaid access and health care utilization and long-term cancer outcomes, such as chronic health conditions and mortality. And additionally, a small study from Stanford University reported a partnership with a community-based nonprofit organization [Jacob's Heart] to improve cancer center-based follow-up for Latinx adolescent and young adult cancer survivors, or AYA survivors. These investigators conducted interviews in the participants' preferred language, with cancer survivors, their parents, and staff from the community organization. They were able to identify important themes around unmet needs for this population, such as challenges with obtaining health care and understanding which providers to see for which health issues, an oncologist or primary care provider, uncertainty about what questions to ask these providers, difficulty adjusting to life after treatment, and understanding the late effects of cancer on the whole family, economically and mentally. For example, issues with parental job loss, financial strain, or impacts on other siblings in the home. However, these investigators also found supportive themes such as gratitude, strength, and support. Addressing these barriers is important for families and communities to promote follow-up after cancer treatment. This study was particularly unique because of its ability to successfully partner with a community organization to reach out and provide opportunities to improve care for Latinx AYA cancer survivors. The studies highlighted here and presented at this year's ASCO Annual Meeting focused on identifying barriers to equitable care for all children diagnosed with cancer and has laid the groundwork for future investigations to address these issues for children and families during treatment as well as after treatment and during survivorship. Thank you for listening to this brief summary of some of the exciting and novel research in pediatric oncology presented at the 2023 ASCO Annual Meeting. ASCO: Thank you, Dr. Mulrooney. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

Fashion journalist Jeanne Beker has been in the public eye for more than 50 years, most notably as a globetrotting reporter interviewing some of the world's highest-profile designers and models, as well as entertainers the likes of Paul McCartney and Bob Hope. But for the last year, Beker, now 71, has turned the camera on her own story—as a breast cancer patient. She's been extremely public about her diagnosis, chemotherapy and radiation treatments, and surgery. And now, she's advocating for better (and earlier) screening for women with dense breasts. Two weeks ago, Beker completed her year of cancer treatments at the Princess Margaret Hospital in Toronto. But that challenge hasn't stopped her from starting to write a new book, hosting her Style Matters television show and making countless appearances at fundraisers for breast cancer and other good causes. Beker joins The CJN Daily to discuss where she got her determination and how she's found a renewed gratitude for life. What we talked about Follow Jeanne Beker on her Instagram account or her website Read The CJN's coverage of Jeanne Beker's career from emceeing the Zareinu fashion shows, to winning many awards Hear The CJN Daily's interview with Jeanne Beker's cancer authority, Dr. Paula Gordon, on why women with dense breasts should get screened beginning at 40 Credits The CJN Daily is written and hosted by Ellin Bessner (@ebessner on Twitter). Zachary Kauffman is the producer. Michael Fraiman is the executive producer. Our theme music is by Dov Beck-Levine. Our title sponsor is Metropia. We're a member of The CJN Podcast Network. To subscribe to this podcast, please watch this video. Donate to The CJN and receive a charitable tax receipt by clicking here. This podcast is powered by Pinecast.

One of India's first supermodels. Actor. Cancer survivor. Mother of twins through surrogacy. Woman of no fixed address. Today I am honored to interview cross cultural phenomenon Lisa Ray. She is an internationally acclaimed performer, philanthropist and star with a reputation for taking on challenging issue-oriented films. Raised in Canada by an Indian father and Polish mother, Ray was discovered while on vacation in India and went on to become not only one of the most successful cover models and celebrities in India but also an acclaimed, award-winning actress who starred in Canada's Oscar nominated film, Water, amongst other prestigious credits. Named one of the ‘Ten most beautiful Indian women of the millenium' by a Times of India poll, Ray cemented her profile as an iconic figure in India before leaving for drama school in London and opportunities around the world. Along the way, Ray found time along the way to host her own entertainment show in India, filmed a landmark music video for Nusrat Fateh Ali Khan, and became the enduring brand ambassador for Rado Watches. In 2009, Ray attended the Toronto International Film Festival in support of her work in two films. The event marked an important public announcement, in which Ray chose to share her diagnosis of Multiple Myeloma with media and the public. The outpouring of support was immediate and overwhelming. She also started a blog (‘The Yellow Diaries') to share her cancer experiences. Her forthrightness and humour in navigating a difficult illness have earned her the attention and respect of people from all corners of the world, as well as ‘The Voice Achievers Award, 2009' and ‘The Hope Award, 2010'. Ray went on to help raise funds for the establishment of the first research chair for Multiple Myeloma at Princess Margaret Hospital in Toronto. Ray's philanthropic interests range from taking part in the on-air drive for SickKids Hospital to Ambassador of Plan Canada's ‘Because I Am A Girl' campaign, a global movement that supports the rights of girls around the world. In 2019, Lisa released her memoirs Close to The Bone. “An unflinching, deeply moving account of her nomadic existence: her entry into the Indian entertainment industry at sixteen; her relationship with her Bengali father and Polish mother; life on the movie sets and her brush with the Oscars; her battle with eating disorders; being diagnosed with multiple myeloma at thirty-seven; her spiritual quest; lovers and traitors, mentors and dream-makers; and the heartaches and triumphs along the way. It is also about Lisa's quest for love. Funny, charming, and gut-wrenchingly honest all at once, Close to the Bone is Lisa Ray's brave and inspiring story of a life lived on her terms.” Lisa and her husband Jason Dehni have two lovely daughters, Sufi and Soleil.

Dr. Kate Bartlett is a perinatal pathologist currently based in Auckland. Having studied in Otago Medical School, she began her house surgeon years in New Plymouth before then working in Auckland. She completed her perinatal and paediatric pathology fellowship at Princess Margaret Hospital in Perth, before returning to New Zealand where she has been a consultant for more than a decade. In this episode, we discuss her choosing pathology, the training requirements and examinations for pathology, subspecialising in perinatal/paediatric pathology, challenges/lowlights/highlights of her career, part-time work, public vs private in NZ vs overseas and job prospects/opportunities for budding pathologists.Support the showAs always, if you have any feedback or queries, or if you would like to get in touch with the speaker, feel free to get in touch at doctornos@pm.me. Audio credit:Bliss by Luke Bergs https://soundcloud.com/bergscloudCreative Commons — Attribution-ShareAlike 3.0 Unported — CC BY-SA 3.0Free Download / Stream: https://bit.ly/33DJFs9Music promoted by Audio Library https://youtu.be/e9aXhBQDT9Y

Damian Shepherd - Director State Records State Records Office of Western Australia Chats about the  ‘Memories of Princess Margaret Hospital' on Feb 5 2023See omnystudio.com/listener for privacy information.

The overnight show's favourite music journalist, broadcaster and publicist That Eric Alper joins us as he does every week, and talks about the music news of the week. We get a look "Inside Natalie" with Toronto-based Comedian Natalie Norman  Riding the Enbridge Ride to Conquer Cancer with Sabrina Bennett, Honourary Chair and Oncology Nurse at The Princess Margaret Hospital.

Today's podcast is with the Neurosurgeon (yes, Neurosurgeon) Dr Alex Koefman . Alex has undertaken specialist training in neurosurgery throughout Australia, including The Canberra Hospital, the Royal Prince Alfred Hospital in Sydney, the Sir Charles Gairdner Hospital and Princess Margaret Hospital for Children in Perth, and the Princess Alexandra, Royal Brisbane, and Lady Cilento Children's Hospitals in Brisbane. During this time, Alex was trained and mentored by many of Australia's most senior subspecialty neurosurgeons and today we discuss his journey to Neurosurgery and what it's like opening up peoples' brains! 

In this episode, we chatted with Drs. Wesley Francis, Don Major, and Greg Padmore. These fantastic surgeons came from the Carribean to train in North America, and we were curious to explore what their experience was like and how they used their training to improve surgical care when they returned home. Links: 1. https://www.ahpba.org/ 2. Cancer Surgery Centre Bahamas - https://cancersurgerybahamas.com/ 3. https://www.barbadosadvocate.com/news/qeh-surgeon-breakthrough-cancer-operation Bios: Dr. Wesley Francis is a graduate of the University of the West Indies (Mona). He did his surgical residency at Wayne State University (Detroit, MI) and completed a Surgical Oncology Fellowship at Tom Baker Cancer Center in Calgary Alberta. He is currently a Consultant Surgical Oncologist at the Princess Margaret Hospital in Nassau Bahamas where he also serves as the Director of Operating Room. He also serves as the Director of the Bahamas National Cancer Registry. Dr. Don Major is a graduate of University of the West Indies (St Augustine). He did his surgical residency at UWI Bahamas where he became the first Bahamian to complete the UWI Bahamas surgical residency program. He completed his surgical oncology and hepatobiliary (HPB) fellowship at the Tom Baker Cancer Center in Calgary Alberta. He is currently a Consultant Surgical Oncologist and Hepatobiliary surgeon at the Princess Margaret Hospital. Dr. Greg Padmore, a 2011 MBBS graduate who completed his pre-clinical years at The UWI Mona Campus and his clinical years at the Cave Hill Campus in Barbados. He is finishing up a two-year Fellowship at the University of Calgary, Canada, where he is undergoing subspecialty training in Hepato-pancreato-biliary Surgery to be followed by Surgical Oncology. He was the 2012 Intern of the Year in Barbados.

Inthis episode, Dr. Gary Sherman has an enlightening conversation with Fay Hosseini, Pharm D.Fay was born in Iran and raised in Canada. Fay completed her Bachelor of Science in Pharmacy at the University of Toronto and spent about 2.5 years working at Princess Margaret Hospital, which is cancer institution affiliated with the University of Toronto. Fay then moved to Vancouver, British Columbia, to complete her Clinical Pharmacy Residency Program which was followed by a Doctor of Pharmacy Degree program at the University of British Columbia. She then moved to Seattle, Washington in the latter part of 2010, where she introduced clinical pharmacy services in the emergency department at the University of Washington Medical Center. In August of 2012, Fay took a position in the emergency department at Harborview Medical Center (a level 1 trauma center) where she successfully introduced clinical pharmacy services in the emergency department at that site as well. Fay has received the Staff Recognition Award in 2012-2017 and 2019 – 2021, highlighting outstanding dedication and commitment to the service of emergency medicine at Harborview Medical Center. Most recently Fay has formally trained at the Life Coach School and we will explore what she has discovered as a life coach today both in her own life and in playing a profoundly important role in the lives of her coaching clients. 

This week's guest is Dr. Marcus Bernardini - Princess Margaret Hospital - Road Hockey to Conquer Cancer.

  Dr Eve Tiong believes in going above and beyond for her patients. Through both personal experience and her work in oncology, she is passionate about delivering exceptional holistic care to patients throughout treatment and beyond.   Dr Eve Tiong is an experienced radiation oncologist at Icon Cancer Centre Midland and Icon Cancer Centre Rockingham. She completed her Bachelor of Medicine, Bachelor of Surgery (MBBS) at the University of New South Wales before establishing her radiation oncology career in Singapore at the National Cancer Centre and National University Hospital in 2009. Returning to Australia, Dr Tiong continued her specialist radiation oncology training at Sydney's Liverpool Hospital and The Canberra Hospital. She was awarded fellowship to the Royal Australian and New Zealand College of Radiologists (FRANZCR) in 2015. Dr Tiong undertook her radiation oncology fellowship (genitourinary and gastrointestinal malignancies, lymphoma and sarcoma) at the Princess Margaret Hospital in Toronto, Canada. She has published on review articles for sarcoma and prostate cancer, and on e-health strategies for breast cancer survivors. Dr Tiong maintains an active interest in cancer education and regularly provides community and GP information sessions about lung cancer (in Chinese), prostate cancer and breast cancer. She is experienced in utilising advanced techniques such as stereotactic radiation therapy, MRI-simulation and image guided radiotherapy. Dr Tiong developed the stereotactic body radiation therapy technique to treat prostate and lung cancers at Icon Rockingham and Icon Midland. Dr Tiong is also proficient in English and can converse in Mandarin and Malay. She looks forward to working with patients in their language. Her clinical experience covers a broad range of solid tumour malignancies, with special clinical interest in prostate cancer, bladder cancer, breast cancer, gastrointestinal cancer, lung cancer, lymphoma and palliative care.   We are very excited to hear what she has to say and hope you enjoy it. https://iconcancercentre.com.au/doctor/eve-tiong/ https://www.exercisemedicine.org.au/vario-health-clinic https://www.nature.com/articles/s41443-020-00386-4?proof=t https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-020-01473-9 https://cpb-us-w2.wpmucdn.com/sites.wustl.edu/dist/2/1332/files/2014/03/EPIC-QOL-final-kaw-7-11.pdf ----- ---------- If you feel The Penis Project is valuable to you then, please review and subscribe as this will ensure more people get to hear what we have to say. ---------- Websites: https://thepenisproject.org/ https://rshealth.com.au/ http://www.menshealthphysiotherapy.com.au/ http://prost.com.au/ https://www.theyogavine.com.au   Facebook: https://www.facebook.com/Restorativeshealthclinic   Music David Mercy https://open.spotify.com/artist/1HbvnltKu4XbWTmk0kpVB9?si=D1xP5dDVQK-zzNU3rViRWg   Producer Thomas Evans: The SOTA Process https://www.instagram.com/thesotaprocess/ https://open.spotify.com/show/4Jf2IYXRlgfsiqNARsY8fi

Diesmal interviewe ich den Neuroradiologen Dr. Hagen Kitzler vom Universitätsklinikum Carl Gustav Carus Dresden. Er erläutert die Bedeutung der MRT, ihrer Standardisierung und an welchen Verbesserungen geforscht wird.   https://ms-perspektive.de/interview-mit-dr-hagen-kitzler-zur-bedeutung-der-mrt-bei-multipler-sklerose/   Wann macht es Sinn Kontrastmittel einzusetzen? Welche Aussagekraft hat ein Scan vom Gehirn? Wann schaut man sich zusätzlich den Sehnerv an? Und vor welchen Herausforderungen stehen Neuroradiologen bei der Darstellung der Hirnrinde und den Nerven in der Wirbelsäule?   Viele Fragen und noch einige mehr, auf die Dr. Kitzler die Antworten gibt.   Dr. Hagen H. Kitzler ist Funktionsoberarzt am Institut für Interventionelle und Diagnostische Neuroradiologie des UK Dresden, Ärztlicher Leiter für den Bereich MRT-Forschung am CarusNeuroImagingCenter und Leiter einer Forschungsgruppe für die Entwicklung quantitativer MRT-Techniken für die MS und neurodegenerative Erkrankungen. Vorstellung Dr. Kitzler hat zwei Kinder. Sein Sohn war viele Jahre Kruzianern im Dresdner Kreuzchor und engagiert sich gerade als BuFDi (Bundesfreiwilligendienst). Seine Frau ist Kinder- und Jugendpsychaterin in eigener Praxis. Seine Freizeit verbringt er gern in der Natur und generell unter freiem Himmel. Gerade ist er mit seiner Frau und Tochter aus einem Urlaub in Mexiko zurückgekehrt, wo es in die Petén-Region, den Akalché-Wald und zu Stätten der Maya-Kultur ging. Hagen H. Kitzler interessierte bereits früh Biologie und Geschichte und er verbrachte einen Teil seiner Kindheit in Nordafrika, wo seine Eltern als Kinderarzt und Hebamme in der Entwicklungshilfe arbeiteten. Wichtigste Stationen bis zur jetzigen Position? Nach dem Abitur war die erste Station die Pflege schwerstbehinderter Kinder in der Diakonie, was sehr prägend war. Eigentlich wollte Hagen H. Kitzler Biologie studieren, doch durch den Kontakt zum Verhaltensforscher Prof. Günter Tembrock (Humboldt Universität Berlin – HUB) kam es anders. Sein humanethologisches Seminar und sein Umgang mit Studenten prägte ihn seitdem. Hagen H Kitzler studierte Humanmedizin an der HUB und absolvierte seine klinische Ausbildung in Dresden. Es folgten Stationen am Brain Tumor Center des Princess-Margaret-Hospital in Toronto, Kanada und der Traumatologie am Groote-Schuur- Hospital in Kapstadt, Südafrika. Die Dissertation schrieb er in Dresden bei Prof. Reichmann in der Klinik für Neurologie. Dann folgte die Ausbildung zum Neurologen an der Charité in Berlin bei Prof. Karl-Max Einhäupl. Dort arbeitete Dr. Kitzler in der Arbeitsgruppe Neuroimmunologie unter Prof. Frauke Zipp mit Dr. Klaus Schmierer als Tutor an einem MRT-Projekt. Weiter ging es zu einer Hospitation in die Neuroradiologie der Charité bei Prof. R. Lehmann, die dann zum Wechsel der Ausbildung vom Neurologen zum Neuroradiologen führte. Bei der Rückkehr nach Dresden startete Dr. Kitzler in der Neuroradiologie bei Prof. Rüdiger von Kummer. Dort standen das Schlaganfall-CT und das Tumor-MRT im Fokus. Seine allgemeinradiologische Facharztausbildung führte er in der Radiologie unter Prof. Michael Laniado durch. Im Anschluss ging es in die Neuroradiologie wo er mit der MRT-Forschung begann. Es ging um Diffusions-Tensor-Bildgebung (DTI) zur Rekonstruktion von Fasertrakten, was zur Vorbereitung der Operationen von Gehirntumoren benötigt wird. Er traf Prof. Tjalf Ziemssen wieder, den er bereits von früher kannte und der gerade das MS-Zentrum in Dresden aufbaute. Beide begannen intensiv miteinander wissenschaftlich und für die diagnostische Patientenversorgung zu koperieren. Dank Prof. Rüdiger von Kummerer konnte Hagen Kitzler von 2007 bis 2009 an die University of Western Ontario nach London, Ontario, Kanada gehen, wo er als Postdoc in der Biophysik und Neuroradiologie forschte. Dort wurde zum ersten Mal eine neue Form der Myelinbildgebung (mcDESPOT), die eine 3D-Aufnahme bei MS ermöglicht angewendet. Mit seiner Rückkehr nach Dresden transferierte er diese Technik an das Uniklinikum Dresden, startet eine dazugehörige Forschungsgruppe und initiierte internationale Kooperationen. Es folgte die Facharztausbildung zum Neuroradiologen und Master of Science für klinische Forschung an der Dresden International University. Persönliche Motivation für Beruf? Meine Zeit mit schwerstbehinderten Kindern war Ausschlag dafür, einen Beruf zu ergreifen, um etwas gegen chronische Leiden zu tun. Warum ist die MRT so gut als diagnostische Methode bei MS geeignet? Die Technik ist ursprünglich eigentlich eine Stoffprobenanalyse, die aufgrund der elektromagnetischen Kennung funktioniert, aber es kommt später zur Nutzung für die Bilderzeugung, weil Stoffe sich untereinander beeinflussen, beispielsweise Wasser. Und wir bestehen zu 98% aus Wasser (H2O). Können Sie die Begriffe T1, T2 und FLAIR einfach verständlich erklären? Was ist damit gemeint und was misst man? Längs- und Quermagnetisierung sind magnetische Grundeigenschaften. Wenn Stoffe elektromagnetisch angeregt und ausgerichtet werden, gehen sie zu ihrer charakteristischen Magnetisierung zurück. Die Zeit dieser Relaxation zurück zur Längsmagnetisierung ist die T1-Zeit. Das Gleiche gilt für die Quermagnetisierung. Hier wird die Zeit der Relaxation zurück zur Quermagnetisierung als T2-Zeit beschrieben. Beides kann man zur Bilderzeugung nutzen. FLAIR ist eine Variante der T2-Bildgebung, bei der wir das Wasser unterdrücken, um die krankhaften Veränderungen besser zu sehen, sozusagen zu kontrastieren. Was kann man bisher alles mittels MRT bei MS-Patienten sehen, vergleichen und auswerten? Prinzipiell sehen wir die Auswirkungen der für die MS typischen Entzündung, klassisch mit konventioneller MRT als Läsionen bezeichnet. Die Läsionen sind hauptsächlich von Demyelinisierung also Entmarkung geprägt. Außerdem kommt es [Anmerk. Nele Handwerker: unbehandelt] zu einer Abnahme des Hirnvolumens, die schneller verläuft, als bei Gesunden. Wir bemerken aber, dass wir mit immer besseren MRT-Methoden sehr viel mehr Details erkennen können, wie spezielle Veränderungen der Hirnrinde, Läsionen, die chronisch aktiv sind aber auch messbare Dinge wie den Myelingehalt oder die Dicke der Nervenzellfortsätze, der Axone. Wenn es sinnvolle Messungen sind, nennt man das dann Biomarker und dazu forschen wir. Wann ist eine Kontrastmittelgabe sinnvoll und was kann man dadurch sehen? Wenn eine starke Entzündung im Gehirn auftritt, verliert es dort kurzzeitig die Fähigkeit, den Übertritt von Stoffen aus dem Blut zu kontrollieren. Man macht sich das zunutze, um die Entzündung aufzuzeigen, da auch Kontrastmittel kurzzeitig dorthin gelangen. Macht es Sinn immer alle Bereiche zu untersuchen? Nein, macht es nicht. Das Gehirn sollte regelmäßig untersucht werden, die Wirbelsäule nur bei Symptomen. Und wenn es um den Sehnerv, die Orbita geht, wird das nur zur ersten Diagnostik gemacht. Wie genau kann man Läsionen im MRT konkreten Symptomen beim Patienten zuordnen? Wenig, da nur ein Teil eindeutige Funktionen trägt. Das Gehirn ist in der Lage sich flexibel anzupassen, was ein großer Vorteil ist. Ein paar Funktionen, wie Bewegung, Sehen und Hören sind jedoch an definierten Stellen im Gehirn zu finden. Auf welche Schlagworte oder Passagen der MRT-Auswertung sollten wir MS-Patienten achten? Neue oder vergrößerte T2-Läsionen. Zunahme von T1-Läsionen, gegebenenfalls Kontrastmittel-Enhancement (Anreicherung) und die Beschreibung zur Messung der Hirnatrophie (Hirnvolumenminderung). Wichtig: Falls die MS erst viel später diagnostiziert wurde, ist der Anfangswert beim Hirnvolumen höchstwahrscheinlich unter dem Altersniveau. Dann geht es darum, ihn auf diesem Level zu halten mit Hilfe der Therapie und einem gesunden Lebenswandel. Wie wichtig ist die Standardisierung beim MRT, um eine Aussage über den Krankheitsverlauf und Wirksamkeit von Therapien treffen zu können? Enorm wichtig. Durch die Standardisierung kann man wirklich sehen, was im Gehirn passiert, weil das dann die einzigen Unterschiede sind und nicht zusätzlich noch Einflüsse der Qualität der Aufnahmen (Details, Schichtdicke, etc.). Wie intensiv und auf in welcher Weise arbeiten sie mit den Neurologen vom MS-Zentrum zusammen? Die MRT-Diagnostik arbeitet sehr intensiv mit dem MSZ zusammen. Es ist fast wie eine Familie. Ich kenne Prof. Tjalf Ziemssen seit meiner Studentenzeit. Wichtig sind der regelmäßige Austausch und die Patientenbesprechungen. Wo liegen die Grenzen vom MRT? Was kann man (noch) nicht darstellen? Und woran forschen sie als Neuroradiologe? Der Kortex, die Hirnrinde, ist noch eine Nuss, die wir knacken müssen und das Rückenmark stellt uns vor biophysikalische Probleme. Dort passiert auch Aktivität durch die Multiple Sklerose, die wir aber leider bisher nur ungenügend darstellen können. Welche Vorteile hätten wir von der standardisierten und computerunterstützten Auswertung der MRT-Bilder? Dass wir immer präziser werden und genau beobachten können, wie die individuelle MS-Entwicklung abläuft und damit auch wissen, ob eine Therapie erfolgreich ist oder gewechselt werden sollte. Wie können wir als MS-Patienten bei diesem Vorhaben helfen? Bislang muss man als Patient zustimmen, da wir uns in der Erprobung beziehungsweise der Einführung in Alltag befinden. Das heißt, die computer-assistierte Software ist noch im Prototypen-Stadium. Bitte nehmen sie an den entsprechenden Studien teil, das hilft uns beim Forschen und stetig besser werden. Welchen Durchbruch wünschen Sie sich für die Forschung und Behandlung der MS in den kommenden 5 Jahren? Für die Behandlung, dass es hochpotente, die Defekte reparierende Mittel, zur Remyelinisierung gibt. Für die Bildgebung wünsche ich mir, dass wir alles Gelernte aus dem Kopf auch auf die Wirbelsäule übertragen können. Blitzlicht-Runde Was war der beste Ratschlag, den Sie jemals erhalten haben? Von meinem Vater MR Dr. Heinz Kitzler: „Such dir ein kleines Spezialgebiet, um etwas Wirksames zu leisten“. Von Prof. Rüdiger von Kummer zum Auslandsaufenthalt: „Junge, geh (zum Forschen) mal woanders hin!“ Wie lautet Ihr aktuelles Lebensmotto? Freude am Lernen, Spaß bei der Arbeit. Mit welcher Person würden Sie gern einmal ein Kamingespräch führen und zu welchem Thema? Mit Prof. Robert Koch, darüber was ihn motiviert hat. Und gern noch einmal Prof. Günter Tembrock, um ihm zu zeigen welches Vorbild er für mich war und was ich als Hochschullehrer heute ähnlich dem mache, wie er damals. Vervollständigen Sie den Satz: „Für mich ist die Multiple Sklerose…eine Herausforderung und Ansporn.“ Welches Buch oder Hörbuch, das Sie kürzlich gelesen haben, können Sie uns empfehlen und worum geht es? Aus meinem Sommerurlaub: Ulrike Peters „Das Alte Mexiko: und seine Hochkulturen“ – Spannend daran ist, dass es auch zeigt, wie die alten Kulturen bis heute Land, Leben und Leute prägen. Möchten Sie den Hörerinnen und Hörern noch etwas mit auf dem Weg geben? Fragen sie, wie ihr Gehirn aussieht. Ihr Neuroradiologe wird es ihnen zeigen. Informieren sie sich, lernen sie stetig dazu. Denn ein informierter Patient, ist der beste Patient. Wenn wir als Team zusammenarbeiten, macht es beiden Seiten mehr Spaß und es gelingt uns effektiver gegen die MS vorzugehen. Wie erreicht man die Neuroradiologie am Universitätsklinikum Dresden am besten? Auf der Webseite der Neuroradiologie oder telefonisch unter 0351 458-13202. ++++++++++++++++++++ Vielen Dank an Dr. Hagen H. Kitzler für das geführte Interview und all die Informationen zur MRT-Untersuchung. Bestmögliche Gesundheit wünscht dir, Nele Mehr Informationen rund um das Thema MS erhältst du in meinem kostenlosen Newsletter. Hier findest du eine Übersicht zu allen bisher veröffentlichten Podcastfolgen.

This week, we're joined by Dr. Paola Cubillos - Colombian-Canadian integrative medicine physician, Medical Cannabis doctor and educator.We investigate the existing theory and evidence base behind the concept of ‘The Entourage Effect' as coined by Professor Raphael Mechoulam, alongside the data we need to be able to validate the hypothesis.→ View full show notes, summary, and access resources here: https://www.canverse.global/shownotes/e129About Dr. Paola CubillosDr. Paola Cubillos is a Colombian-Canadian physician, who specializes in integrative medicine. Dr. Cubillos is a graduate from the Universidad del Rosario in Colombia, and holds a postgraduate degree from the Canadian College of Naturopathic Medicine in Canada.In addition to her clinical practice, Dr. Paola has worked in the research field, focusing on broadening the knowledge base in relation to medical cannabis evidence-based applications. She currently offers independent consulting services on research and medical affairs to medical cannabis producers.Dr. Cubillos is a recognized national and international lecturer on issues related to the evidence-based use of medical cannabis and the ethical implications of medical cannabis use and research. She is faculty of several medical cannabis diplomas offered in several universities and independent organizations in South America, such as Universidad del Rosario in Colombia, Universidad de Rosario in Argentina, Universidad Peruana Cayetano Heredia in Perú, Edcannamed in Ecuador and CAMEDA  in Argentina. Dr. Cubillos is also part of the peer review committee of the Journal of Cannabinoid Medicine. Dr. Paola has been president of the research ethics committee of the Princess Margaret Hospital in Toronto, Canada and of the research ethics committee of the Clínica Las Américas in Medellín, Colombia, and is currently a member of the Research Ethics Committee of the Canadian College of Naturopathic Medicine. Dr. Cubillos is a founding member and member of the board of directors and the scientific leader for the Pro Cannabis Colombia Association- Procannacol, and is a member of the Board of Directors of the Asociación Médica Colombiana de Cannabis Medicinal - ASOMEDCCAM.Quotables“We cannot pretend that by learning or knowing the function of the endocannabinoid system, we can expect cannabis to work in the same way” 10:20“It is the responsibility of everybody in the industry to collect as much standardised data from these products as possible so we can keep feeding [the amount of] data” 30:40

In this episode of our podcast, we are joined by a very special guest, Dr. John Kuruvilla, who is an Associate Professor of Medicine at the University of Toronto and a Clinical Investigator in the Division of Medical Oncology and Hematology at Princess Margaret Hospital in Toronto. We discuss:The current treatment of classical Hodgkin's Lymphoma The use of checkpoint inhibitors for these patients Results of the KEYNOTE-204 trial, a randomized phase III trial of pembrolizumab versus brentuximab vedotin in relapsed or refractory Hodgkin's LymphomaHow future research will address some key questions in this areaThis podcast episode is sponsored by Merck Canada.  If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.

Dr. Hayes interviews Dr. Pamela Goodwin on her work in metabolism and cancer.   TRANSCRIPT SPEAKER 1: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement [MUSIC PLAYING]   SPEAKER 2: Welcome to JCO's Cancer Stories, The Art of Oncology brought to you by the ASCO Podcast Network, a collection of nine programs covering a range of educational and scientific content and offering enriching insight into the world of cancer care. You can find all of this shows, including this one, podcast.asco.org. Today my guest on this podcast is Pam Goodwin. Dr. Goodwin was instrumental in the consideration of metabolism, exercise, and diet for prevention and/or treatment of breast, and for that matter, other cancers. Dr. Goodwin received her undergraduate medical degree from the University of Ottawa, and then she did a residency in internal medicine at the University of Toronto, where she also did a year residency in pathology, which I was unaware of. She went on to train in oncology at Princess Margaret Hospital in Toronto, and she spent a year as a research fellow with, in my opinion, the legendary Dr. Norman Boyd. She's on a clinical appointment at Mount Sinai Hospital in Toronto, where she directed the breast program for 15 years. And she's remained on faculty for the University of Toronto since 1986, where she is now the Marvelle Koffler Chair in breast research and a professor in the departments of medicine and clinical epidemiology. She's won many, many awards for her contributions to science, but perhaps most germane to this discussion-- and I was unaware-- she was named a star in nutrition and cancer by the United States National Cancer Institute a few years ago. She's authored over 200 peer reviewed papers. And she serves as the current editor in chief of the Journal of the National Cancer Institute Cancer Spectrum, and she's also deputy director of JNCI. By the way, she receives research funding in collaborations with Epic Science but has no other declarations of conflicts. Dr. Goodwin, welcome to our program today. PAM GOODWIN: Thank you. It's a pleasure to be here. SPEAKER 2: So let's start with a [INAUDIBLE] question that I ask almost everybody in this series. And that is, tell us a little about yourself and why oncology. Was there a light bulb that went on, or you knew you were going to be an oncologists from the time you were in kindergarten? PAM GOODWIN: Well, I was born in Ottawa. And when I was a young girl at five years old, we moved into the country. And it was just outside of Ottawa, but it's now called Kanata. But at the time, it was a very rural area. And I started my education in a one-room schoolhouse. By the time I was halfway through my schooling, they put a division down the middle of the room and it became a two-room schoolhouse. But from the very beginning, I remember in grade 1 sitting at the back of my row-- each grade had a row-- and I would listen to the lesson from my row. And the teacher would move to the next row, and I would listen to that lesson, and then I would listen to the next lesson. I always wanted to learn more. I became interested in oncology for a reason that many oncologists have. My mother had cancer and died when I was still in school. And-- jeez, still emotional. And it really made me realize that-- at the time, cancer was almost uniformly fatal. It made me realize that there was a lot of work to be done in the area of cancer. So I very early on decided that I was going to do medicine and that I was going to do oncology, and I never looked back. SPEAKER 2: So neither of your parents was a physician? PAM GOODWIN: No, no. My mother actually worked in the finance department on Parliament Hill for the government of Canada. And my father, in the 1950s, worked on computers for the Department of National Defense. So no medical people there at all. SPEAKER 2: Well, at least it sounds like there was some science behind you. And when you went into oncology then, were you just dedicated to breast cancer because of the history you just gave us, or was there somebody who talked you into being a breast cancer person? PAM GOODWIN: I think Norman Boyd had one of the biggest influences me. My mother didn't have breast cancer, she had myeloma. But Norman, at the time, was at Princess Margaret Hospital and was very interested in diet and breast cancer risk. And I was very interested in the role of the patient in cancer from the very beginning. I thought I might end up doing research in quality of life, because that was an emerging field at the time. But I became very interested in the host factors in obesity, metabolism. And I chose to focus on how these factors impacted the clinical course of cancer for the most part, and I focused on breast cancer. At the time, it was way, way out there to work in this area. And one of my biggest challenges as a new investigator and a new staff person was to be sure that people didn't think I was a little bit of a quack by working in this area. SPEAKER 2: Actually, I have two follow up questions for that, and I'll get to that in just a moment. But can you tell us a little more about Dr. Boyd. I mentioned him earlier as being legendary, but a lot of our listeners may not know who he is and what he's done. PAM GOODWIN: So Norman Boyd was a medical oncologist at Princess Margaret Hospital who became a clinician scientist over the years. He was very interested in the role of dietary fat in breast cancer and actually conducted a randomized trial of dietary fat reduction, which, unfortunately, didn't show a beneficial effect on breast cancer. But he was one of the grandfathers of the mammographic density breast cancer risk association. And he did a very large amount of work confirming that association, quantifying that association, and identifying how it made independent contributions to breast cancer risk over and above family history, for example. SPEAKER 2: I want to say, I have-- obviously, I think you can tell-- enormous respect for Dr. Boyd. He's truly a giant. However, he's caused more trouble in the United States than he knows, because every woman has a mammogram. If she has dense breasts, she gets a little piece of paper saying, speak to your doctor about this. And then we say, I don't know what to do about that. PAM GOODWIN: That's right. That's right. That happens in Canada sometimes too. SPEAKER 2: So you've talked about Dr. Boyd being a stimulus. And you sort of hinted on this. Were there obstacles? I can imagine mentors at the time at Princess Margaret or other places saying, are you crazy? This will go nowhere. You're wasting your career. PAM GOODWIN: Well, I think a lot of people thought that it was a little bit crazy. I think a lot of people thought that it was possibly these people were being under dosed with chemotherapy, that the obesity cancer link wasn't a true biologic association. And that's one of the reasons that I have practiced at a general hospital my whole life. At a general hospital, we have a very strong diabetes and endocrinology department. And they fully understood that these factors could be important. They had seen the impact of diabetes on a host of organs-- end organ disease in the kidney, for example-- and they were very open to this type of research. And I was actually recruited to Mount Sinai Hospital by a guy called Lou Siminovitch, who was a molecular biologist. He had just set up a new research institute at Mount Sinai Hospital. And even though he was not an MD, he wasn't a clinician, he would look at all of my grants and ask the most important question, find the fatal flaw that needed to be fixed before it went in. And Lou continued to support me throughout my career. He died just a couple of weeks ago just shy of his 101st birthday. SPEAKER 2: Oh my. That's great. So you mentioned your grants. Was it hard to get funded early on when you started this? PAM GOODWIN: With some organizations, yes it was. But I think because I always presented this as a biologic association and my focus, at least early on, was to try to identify what was the biologic link between obesity and breast cancer, I think my grants were somewhat better received. I think I always had hypotheses relating to the biomarkers and not just to the prognostic association. Now it wasn't always easy, because my first study was a prospective study of obesity and breast cancer. And towards the middle of the 1990s, we confirmed the association and we looked at biomarkers. We collected fasting blood during the study. We looked at biomarkers focusing on insulin, because there was some emerging evidence that insulin might be associated with cancer. And we actually showed that insulin was strongly associated with obesity and was a stronger predictor of breast cancer recurrence and death than obesity. So as a young staff person-- I think I was an associate professor at the time-- I wrote that up and I sent it to The New England Journal of Medicine, thinking that I really had a great finding there. And New England gave me three reviews. Two of them were glowing. They were fantastic, really nothing to change. And the third one said, I see nothing wrong with this paper, I simply don't believe the results. And New England rejected it. SPEAKER 2: It's always the third reviewer. PAM GOODWIN: That's right. But it took another three years to get it published in JCO. And it's now my most highly cited paper, so go figure. SPEAKER 2: That's interesting. So you talked a bit about the biology. Again for our listeners, my impression is not just that obese people get cancer, but that there is an underlying biology that connects them. Can you go through what your work to show that, and others for that matter. PAM GOODWIN: Yeah, so it's a really complicated association. And the biology of obesity is complicated. There is an alteration or a change in adipose tissue in individuals that are obese, and that's associated with a change in physiology. And both of those factors can then impact the development and prognosis or clinical course of breast cancer. We focused more on the physiology. We've looked at insulin, which I think is now accepted as a growth factor in breast cancer. Most breast cancers express insulin receptors on their surface and insulin that is circulating signals with those receptors to turn on the PI3 kinase pathway. Hyperglycemia, which is associated with obesity, may also change cellular metabolism. And there's a lot of people that have been focusing on inflammation in the adipose tissue. Andy Dannenberg's group in New York has probably been the main people in this area. We've recently looked at that, and we've actually found-- Martin Chang, a pathologist who worked with me at Sinai, and he's now in Vermont, he recently found that the type cellular response to obesity that occurs in adipose tissue may actually determine the physiologic response to obesity and whether obesity impacts breast cancer outcomes. So in other words, if there are CD68 positive macrophages in adipose tissue, you're going to have insulin resistance and you're going to have poor breast cancer outcomes. But for another woman who has the same BMI, if she has an absence of those CD68 positive macrophages in the adipose tissue, she will not have insulin resistance and she will not have worse breast cancer outcomes. So we're trying to focus there on what is the link between the adipose tissue response and the physiologic response and what drives that. SPEAKER 2: I think almost everybody listening to this podcast knows that over the last 15 or 20 years, we've really broken breast cancer into a number of different kinds of cancers. In fact, I really believe that they all happen to be different cancers that happen to start in one anatomic site-- the breast-- as opposed to being all breast cancers. Have you seen differences in the emergence or potential treatment of different subtypes related to obesity or obesity management? PAM GOODWIN: So in some of our earlier work, we actually found that obesity was "perhaps" a little bit more prognostically important in ER negative breast cancer. And I put the word perhaps in quotation marks there. I think more recent work has not shown that, and that obesity contributes across the spectrum of breast cancer. To the extent that obesity impacts are related to estrogen, then you're going to see a greater impact in hormone receptor positive breast cancer. But the association is really seen across the spectrum of breast cancers. SPEAKER 2: So another question that raises-- and others have addressed this-- do you think it's obesity or specific types of diets that are the culprit? PAM GOODWIN: I think it's obesity. I think diet contributes to body size, and I think the composition of the diet may play a role in the response to obesity. But I think that if you are normal weight and have non-obese physiology, the dietary composition doesn't matter quite as much. I think right now when people are looking at diet, they're no longer looking at the fat content of the diet. They're looking at whether it's a healthy diet, whether there are legumes and nuts and healthy oils, but they're also looking at the glycemic index of the diet. I think all of that contributes, but my read is that obesity is the primary driver of this association. SPEAKER 2: And do you think that once you have obesity, it's too late, losing doesn't help. In other words, this is something that's imprinted early on, because I do want to get into treatment too, but especially for prevention. PAM GOODWIN: So that's an unknown. Steve Hursting's group has actually done an experiment where they had mice that were either fed a normal diet and weren't obese, or were fed an obesogenic diet and became obese. And the ones that became obese, a group of them, half of them were put back on the normal diet and they became non-obese. And then they injected all three groups with cancer cells. And what they found was that the currently obese and the formerly obese mice had tumor growth that was the same and was much greater than the mice that were never obese. And they also found patterns of DNA methylation and gene expression in the mammary fat pad that was similar in the formerly obese and the currently obese mice and different from the never obese mice. That suggests that, perhaps, there may be some carryover after weight loss. But I think we need to be very, very careful. The tumor cells were injected almost immediately after the weight loss. And these were mice, they weren't people. People, I think, are a little bit more complex than mice. SPEAKER 2: I mean, this raises-- actually, I have to say that this entire series for me has been, what if I was in a cab with these people who have been experts and pioneers in a field and I can just ask ask them any questions I want to. These are questions I've been wanting to ask you for 20 years, but we never had the opportunity. So the other thing is it's a little bit like early pregnancy. We know there is something about early pregnancy that imprints a cancer reduction compared to late pregnancy. And as you know the Russos have worked on this for years and years. And I've wondered if that's the case with obesity, but now I'm going to [INAUDIBLE] myself instead of you. It's just something I've thought about for a long time. PAM GOODWIN: We're not going to know until we get the results of some studies. The BWEL study led by Jennifer Ligibel looks at weight loss after breast cancer diagnosis. It's fully accrued. It's a randomized trial. It will give us some definitive information. But our group did a small randomized trial called the LISA study, which were reported out about a year ago. And in that study, we actually showed that there was a reduced risk of breast cancer recurrence in women that were randomized to the dietary-- the weight loss intervention arm. The hazard ratio was 0.71. We'd hypothesized a hazard ratio of 0.76. So it looked good, but we did not complete accrual on that study. So we didn't have the power to conclude that the effect that we saw was actually significant. But I actually think that those results are-- I think they're going to lead us in the direction that we hope to see in the BWEL study. In other words, I think that the effect of obesity will not be fully baked in and that there may be some ability to reverse it. We know that losing even 10% of weight will reduce insulin, for example, by 20% to 30%. We know we can see major changes in physiology when we see weight loss. SPEAKER 2: So in your work with [INAUDIBLE], so go back to biology, and you had an opportunity then to look at things like methylation patterns before and after weight loss in cancer cells, or what's getting turned on. You talked about the CILs in macrophage infiltration, but are there things going on in the cancer cells themselves-- or the normal cells for that matter-- that make them more or less susceptible to going on to become nasty cancers? PAM GOODWIN: So that's a little bit beyond my focus. In the BWEL study, blood is being collected repeatedly. So we'll at least be able to look at those changes in lymphocytes, for example. When you're looking at the adjuvant setting, there's no tumor to rebiopsy. And I'm not convinced that the obesity link is the same in the metastatic setting as it is in the adjuvant setting. Once you get into the metastatic setting, the presence of tumor itself may alter metabolism and may impact a lot of the factors that we're looking look at. SPEAKER 2: I'd like to ask you to look forward a little bit now too, because especially in your early work with epidemiology and a focus on lifestyle changes and weight loss, do you think that's going to be where the magic bone will be, or will it be a drug that people can take? I know you've worked quite closely with the Metformin. And imagine you looked in a crystal ball here, I know it's cloudy, but maybe you can give us some insight. PAM GOODWIN: Well, we've looked at Metformin initially because it was an insulin lowering drug. And then Grahame Hardie identified the AMP kinase mechanism of action, and now there's a host of direct antitumor effects that have been reported with Metformin. I think that Metformin in many ways is an anti-obesity physiology drug. It improves much of the physiology associated with obesity. As you know, we've done work showing that it lowers insulin in non-diabetic patients who have breast cancer. We've also done a neoadjuvant window of opportunity study, where patients were given Metformin for the two weeks between diagnosis and definitive surgery. And we showed that Metformin actually lowered T67 and increased apoptosis in the cancer cell. So that was the time when we could look at the cancer cells before and after drug administration. So I think we may see some direct-- or we may see some tumor effects. As you know, we have the large MA-32 adjuvant trial-- 3,600 patients-- which is about to be analyzed. It will likely be analyzed in the next two to three months, and we'll have a definitive answer as to whether Metformin will improve breast cancer outcomes. And because we're looking at contralateral breast cancers, we can also look at whether it impacts the development of breast cancer. SPEAKER 2: At night, do you look up at the ceiling and worry about things like everolimus and alpelisib that actually block the insulin pathway, and then we see hyperglycemia? I don't know if you've treated many people with alpelisib, but hyperglycemia is one of the major consequences of that. Could we actually be in a vicious cycle with using these drugs, or am I reaching too far? PAM GOODWIN: No, I worry about it. I do. It's the same with the IGF1 receptor blockers. I think that sometimes we don't look at the impact of a drug that we believe targets the tumor on the patient's physiology, and the patient's physiology may then actually impede the ability of the drug to treat the breast cancer. If we look at the use of, for example, aromatase inhibitors in premenopausal women, they raise the estrogen levels and the tumor may progress more quickly. We have an example of that. And I think whenever we're doing anything, we need to look beyond the drug itself to the impact-- the drug and the tumor to the impact it has on the patients. I mean, one of the really interesting things that I've seen recently is that some of the PD-L1 inhibitors, when you look at them used to treat cancers other than breast cancer-- I don't think we have this information yet in breast cancer-- being obese actually predicts a better response. So there's something about the synergy between the PD-L1 inhibitor and the obese physiology that makes the PD-L1 inhibitor work better. And some people think it's leptin that is playing a role, but I don't think that's been definitively established. SPEAKER 2: I was not aware of that. Actually, when I was at the Dana-Farber, Chuck Scher, who discovered PD, Platelet-Derived, growth factor, was an endocrinologist. He's a PhD, but he's an endocrinologist by training. And he used to tell me the cancer is just endocrinology gone wild, so you need to understand endocrinology if you're going to be an oncologist. And I'm learning that in spades now 40 years later. PAM GOODWIN: Well, when it comes to breast cancer, yeah, that might be true. Only-- SPEAKER 2: Well, especially in breast cancer, I think. Let's get away from breast cancer for just a moment. I'm towards the end here. And what do you think the role for obesity and diet in other cancers? Do you see such a strong association? And do you have optimism that the kinds of things you're doing in breast cancer will spill over to the others? PAM GOODWIN: So I think obesity is important for cancer in general. I think obesity is associated with increased risk of most types of cancer. And I think it's even more important in cancers like endometrial cancer than it is in breast cancer. I think that what we're learning about obesity and breast cancer will be applicable to multiple other types of cancers. One of the big things we need to think about, though, is that we're in the midst of an obesity epidemic. And at some point, this becomes a societal issue. Obesity is a bad thing for cancer. It's a bad thing for many other illnesses too. And it's probably contributing to a shortened life expectancy for obese individuals. And we need, as a society, at least in the developed world, to start thinking about what we are going to do to try to reduce obesity, to try to get people to eat healthy and to eat proper portion sizes, and to become physically active or to be more physically active. I put that in a very blunt way, but I think these issues extend far beyond breast cancer, far beyond cancer, and really into our general health and well being. SPEAKER 2: Yes, I agree. I've been fond of saying that I think obesity is the smoking of the next generation. I think we're going to pay the piper for this. PAM GOODWIN: I think you're absolutely right. And I think we have a generation that's coming up that maybe has never known proper portion size and knows, at a theoretical level, about healthy eating but doesn't understand how to put it into place and follow a healthy diet and be physically active. And because the obesity epidemic is really just the last generation or generation and a half, we should be able to turn it around. This is not something that's baked into our genes. This is something that we, as a society more so than as individuals, [INAUDIBLE]. SPEAKER 2: Well, and I think when we finally do recognize that and understand how to treat the obesity, people will remember that you were at the forefront-- I don't want to age you-- but 30 or 35 years ago when the whole field got started. So thank you for your courage in going that way. Many of us took the path of least resistance. I don't think you did. Anyway, so thanks for taking time to speak with us today, very much appreciated. And thanks for all you do for the field, and most importantly for our patients. I'm fond of saying that to almost all of our speakers. Without the people who have been on this series, we wouldn't be where we are today. So I'm very appreciative of it. Have a good day. Buh-bye. PAM GOODWIN: You too. Buh-bye. SPEAKER 2: Until next time, thank you for listening to this JCO's Cancer Stories, The Art of Oncology podcast. If you enjoyed what you heard today, don't forget to give us a rating or review on Apple Podcasts or wherever you listen. While you're there, be sure to subscribe so you never miss an episode. JCO's Cancer Stories, The Art of Oncology podcast is just one of ASCO's many podcasts. You can find all the shows at podcast.asco.org. [MUSIC PLAYING]

One of India's first supermodels. Actor. Cancer survivor. Mother of twins through surrogacy. Woman of no fixed address. Today I am honored to interview cross cultural phenomenon Lisa Ray. She is an internationally acclaimed performer, philanthropist and star with a reputation for taking on challenging issue-oriented films. Raised in Canada by an Indian father and Polish mother, Ray was discovered while on vacation in India and went on to become not only one of the most successful cover models and celebrities in India but also an acclaimed, award-winning actress who starred in Canada's Oscar nominated film, Water, amongst other prestigious credits. Named one of the ‘Ten most beautiful Indian women of the millenium' by a Times of India poll, Ray cemented her profile as an iconic figure in India before leaving for drama school in London and opportunities around the world. Along the way, Ray found time along the way to host her own entertainment show in India, filmed a landmark music video for Nusrat Fateh Ali Khan, and became the enduring brand ambassador for Rado Watches. In 2009, Ray attended the Toronto International Film Festival in support of her work in two films. The event marked an important public announcement, in which Ray chose to share her diagnosis of Multiple Myeloma with media and the public. The outpouring of support was immediate and overwhelming. She also started a blog (‘The Yellow Diaries') to share her cancer experiences. Her forthrightness and humour in navigating a difficult illness have earned her the attention and respect of people from all corners of the world, as well as ‘The Voice Achievers Award, 2009' and ‘The Hope Award, 2010'. Ray went on to help raise funds for the establishment of the first research chair for Multiple Myeloma at Princess Margaret Hospital in Toronto. Ray's philanthropic interests range from taking part in the on-air drive for SickKids Hospital to Ambassador of Plan Canada's ‘Because I Am A Girl' campaign, a global movement that supports the rights of girls around the world. In 2019, Lisa released her memoirs Close to The Bone. “An unflinching, deeply moving account of her nomadic existence: her entry into the Indian entertainment industry at sixteen; her relationship with her Bengali father and Polish mother; life on the movie sets and her brush with the Oscars; her battle with eating disorders; being diagnosed with multiple myeloma at thirty-seven; her spiritual quest; lovers and traitors, mentors and dream-makers; and the heartaches and triumphs along the way. It is also about Lisa's quest for love. Funny, charming, and gut-wrenchingly honest all at once, Close to the Bone is Lisa Ray's brave and inspiring story of a life lived on her terms.” Lisa and her husband Jason Dehni have two lovely daughters, Sufi and Soleil.

The next in our Webinar Series: What's New In, in this episode, Dr. Paul Wheatley-Price discusses upcoming treatments, studies breakthroughs, and the future of lung cancer with Dr. Frances Shepherd, MD, FRCPC, Medical Oncologist at Princess Margaret Hospital in Toronto.

In this special episode we continue our webinar series, What's New In: with Dr. Paul Wheatley-Price moderating a discussion of ALK positive lung cancer and treatments. Featuring Dr. Natasha Leighl, BSc, MMSc, MD, Medical Oncologist, Princess Margaret Hospital and Dr. Ross Camidge, MD, PhD, Medical Oncologist, University of Colorado Hospital.

A Christchurch mother fears her daughter won't recover from anorexia because she can't access the treatment she needs. Currently her daughter is in general hospital care, being fed intravenously to stay alive. That family has been told that specialist therapy previously available at Princess Margaret Hospital currently doesnt have any spare beds. Her mother says that treatment was working but stopped at a crucial point.  

A Christchurch mother fears her daughter won't recover from anorexia because she can't access the treatment she needs. Currently her daughter is in general hospital care, being fed intravenously to stay alive. That family has been told that specialist therapy previously available at Princess Margaret Hospital currently doesnt have any spare beds. Her mother says that treatment was working but stopped at a crucial point.  

A new pop-up testing centre will open today in Christchurch after a second worker at the Sudima managed isolation facility tested positive for Covid-19. The testing centre will be in the Princess Margaret Hospital car park offering free tests from 11.30am until 4.30pm. On the other side of the city, there have been queues at a Covid-19 testing station near the Sudima Hotel but RNZ reporter Sally Murphy yesterday found some around the city were not even aware of the community cases. Leeann Watson from the Canterbury Employers' Chamber of Commerce speaks to Corin Dann.

Rick’s career has spanned several decades and seen him lead Canadian divisions for multi-nationals based in Japan (Matsushita Group), France, (Schneider), USA (Emerson), and Germany (Phoenix Contact).More recently, Rick is the founder of Peak Performance Leadership Services.Rick is a sales and leadership executive who combines strong mentoring skills along with coaching tactics with real-world knowledge and experience to assist individuals and organizations alike to PUNCH through their growth ceilings and reach their full potential!Rick’s extensive background in transformational sales growth strategies, execution, and team building has driven needed change in small to large organizations, including creating winning sales processes, focused on consultative and relationship-based selling.Rick is the best selling author of Reinvent Yourself. In this revolutionary self-help guide, the author Rick Denley, a global transformational growth coach, catapults you towards conquering any mess, movement, or mission you are on, through self-reinvention.Rick is a keynote speaker, having spoken on stages around the world. Some of his keynote talks include:• Reinvent Yourself!• Leadership Your Way• Evolution of the Customer• Selling 2.0.Rick believes in giving back and has worked for several years to raise awareness and funds to help cure cancer, including participating in fundraising walks, Conquer Cancer Niagara Ride, and most recently Rick devoted many hours per week for eight months training for to become an amateur fighter and participate in his first bout at the Fight to End Cancer gala event raising over $1M for cancer research and treatments for the Princess Margaret Hospital, a top five in the world cancer facility.Rick lives in Toronto. He has two adult sons whom he coached in competitive hockey for many years with them reaching the ranks of University and Jr A levels of competition. They currently live independently in Toronto with their own careers in music and social work.The best selling author, advisor, speaker, mentor, leader, and coach.Learn more about Rick and Peak Performance Leadership at www.rickdenley.comInfluential Influencers with Mike Saundershttps://businessinnovatorsradio.com/influential-entrepreneurs-with-mike-saunders/Source: https://businessinnovatorsradio.com/interview-with-rick-denley-founder-of-peak-performance-leadership

Rick’s career has spanned several decades and seen him lead Canadian divisions for multi-nationals based in Japan (Matsushita Group), France, (Schneider), USA (Emerson), and Germany (Phoenix Contact).More recently, Rick is the founder of Peak Performance Leadership Services.Rick is a sales and leadership executive who combines strong mentoring skills along with coaching tactics with real-world knowledge and experience to assist individuals and organizations alike to PUNCH through their growth ceilings and reach their full potential!Rick’s extensive background in transformational sales growth strategies, execution, and team building has driven needed change in small to large organizations, including creating winning sales processes, focused on consultative and relationship-based selling.Rick is the best selling author of Reinvent Yourself. In this revolutionary self-help guide, the author Rick Denley, a global transformational growth coach, catapults you towards conquering any mess, movement, or mission you are on, through self-reinvention.Rick is a keynote speaker, having spoken on stages around the world. Some of his keynote talks include:• Reinvent Yourself!• Leadership Your Way• Evolution of the Customer• Selling 2.0.Rick believes in giving back and has worked for several years to raise awareness and funds to help cure cancer, including participating in fundraising walks, Conquer Cancer Niagara Ride, and most recently Rick devoted many hours per week for eight months training for to become an amateur fighter and participate in his first bout at the Fight to End Cancer gala event raising over $1M for cancer research and treatments for the Princess Margaret Hospital, a top five in the world cancer facility.Rick lives in Toronto. He has two adult sons whom he coached in competitive hockey for many years with them reaching the ranks of University and Jr A levels of competition. They currently live independently in Toronto with their own careers in music and social work.The best selling author, advisor, speaker, mentor, leader, and coach.Learn more about Rick and Peak Performance Leadership at www.rickdenley.comInfluential Influencers with Mike Saundershttps://businessinnovatorsradio.com/influential-entrepreneurs-with-mike-saunders/Source: https://businessinnovatorsradio.com/interview-with-rick-denley-founder-of-peak-performance-leadership

Rick’s career has spanned several decades and seen him lead Canadian divisions for multi-nationals based in Japan (Matsushita Group), France, (Schneider), USA (Emerson), and Germany (Phoenix Contact).More recently, Rick is the founder of Peak Performance Leadership Services.Rick is a sales and leadership executive who combines strong mentoring skills along with coaching tactics with real-world knowledge and experience to assist individuals and organizations alike to PUNCH through their growth ceilings and reach their full potential!Rick’s extensive background in transformational sales growth strategies, execution, and team building has driven needed change in small to large organizations, including creating winning sales processes, focused on consultative and relationship-based selling.Rick is the best selling author of Reinvent Yourself. In this revolutionary self-help guide, the author Rick Denley, a global transformational growth coach, catapults you towards conquering any mess, movement, or mission you are on, through self-reinvention.Rick is a keynote speaker, having spoken on stages around the world. Some of his keynote talks include:• Reinvent Yourself!• Leadership Your Way• Evolution of the Customer• Selling 2.0.Rick believes in giving back and has worked for several years to raise awareness and funds to help cure cancer, including participating in fundraising walks, Conquer Cancer Niagara Ride, and most recently Rick devoted many hours per week for eight months training for to become an amateur fighter and participate in his first bout at the Fight to End Cancer gala event raising over $1M for cancer research and treatments for the Princess Margaret Hospital, a top five in the world cancer facility.Rick lives in Toronto. He has two adult sons whom he coached in competitive hockey for many years with them reaching the ranks of University and Jr A levels of competition. They currently live independently in Toronto with their own careers in music and social work.The best selling author, advisor, speaker, mentor, leader, and coach.Learn more about Rick and Peak Performance Leadership at www.rickdenley.comInfluential Influencers with Mike Saundershttps://businessinnovatorsradio.com/influential-entrepreneurs-with-mike-saunders/Source: https://businessinnovatorsradio.com/interview-with-rick-denley-founder-of-peak-performance-leadership

Rick’s career has spanned several decades and seen him lead Canadian divisions for multi-nationals based in Japan (Matsushita Group), France, (Schneider), USA (Emerson), and Germany (Phoenix Contact).More recently, Rick is the founder of Peak Performance Leadership Services.Rick is a sales and leadership executive who combines strong mentoring skills along with coaching tactics with real-world knowledge and experience to assist individuals and organizations alike to PUNCH through their growth ceilings and reach their full potential!Rick’s extensive background in transformational sales growth strategies, execution, and team building has driven needed change in small to large organizations, including creating winning sales processes, focused on consultative and relationship-based selling.Rick is the best selling author of Reinvent Yourself. In this revolutionary self-help guide, the author Rick Denley, a global transformational growth coach, catapults you towards conquering any mess, movement, or mission you are on, through self-reinvention.Rick is a keynote speaker, having spoken on stages around the world. Some of his keynote talks include:• Reinvent Yourself!• Leadership Your Way• Evolution of the Customer• Selling 2.0.Rick believes in giving back and has worked for several years to raise awareness and funds to help cure cancer, including participating in fundraising walks, Conquer Cancer Niagara Ride, and most recently Rick devoted many hours per week for eight months training for to become an amateur fighter and participate in his first bout at the Fight to End Cancer gala event raising over $1M for cancer research and treatments for the Princess Margaret Hospital, a top five in the world cancer facility.Rick lives in Toronto. He has two adult sons whom he coached in competitive hockey for many years with them reaching the ranks of University and Jr A levels of competition. They currently live independently in Toronto with their own careers in music and social work.The best selling author, advisor, speaker, mentor, leader, and coach.Learn more about Rick and Peak Performance Leadership at www.rickdenley.comInfluential Influencers with Mike Saundershttps://businessinnovatorsradio.com/influential-entrepreneurs-with-mike-saunders/Source: https://businessinnovatorsradio.com/interview-with-rick-denley-founder-of-peak-performance-leadership

In this episode, we connect with Tomy Hwang, who currently works as a consultant in Canberra. He shares his stories about his time at UWA, his favorite memories, and the time he spent working with children at Princess Margaret Hospital. We also discuss his transition into consultancy, personal branding for young professionals, and Tomy offers his insight and advice for both present and future young professionals.

Professor Fiona Wood AM is one of Australia’s most innovative and respected surgeons and researchers. A highly skilled plastic and reconstructive surgeon and world leading burns specialist, she has pioneered research and technology development in burns medicine. It was an absolute privilege to be able to discuss her inspirational journey and the approach to life that has enabled her to make a great contribution to the world. We had a connection through our involvements with gymnastics, so it is also great to speak to her about her passion for sport and trampoline gymnastics. Professor Wood’s positions include Director of the Burns Service of Western Australia (BSWA), Consultant Plastic Surgeon at Fiona Stanley Hospital (previously at Royal Perth Hospital) and Princess Margaret Hospital for Children and Winthrop Professor (Burns Injury Research Unit) at the School of Surgery, Faculty of Medicine UWA. She was awarded Member of the Order of Australia in 2003, the Australian Medical Association’s ‘Contribution to Medicine’ award in 2003, the 2003 and 2004 West Australian of the Year and 2005 Australian of the Year. She was voted Australia’s Most Trusted Person for six successive years (2005-2010) and has been recognised as an Australian Living Treasure. Professor Wood believes there is always more that can be done to further the field of burns medicine – new research to be undertaken, new technologies to be discovered and new ways to treat burns survivors. She is on an ongoing quest to continue to make a difference to people’s lives. This is a must-listen episode for those interested in understanding the fascinatingly intricate field of burns medicine and the work of one of Australia's preeminent specialists.

Tanya Sam is a tech savvy businesswoman. Tanya is the Director of Partnerships at TechSquare Labs, a technology startup hub and venture capital fund. Since 2016, TechSquare Labs has invested in over 30 companies and those companies have raised over $300 million dollars in venture capital and generated over $100 million dollars in revenue.Tanya is passionate about creating pathways to bring more women and minorities into business and technology.  She cofounded BuiltxWomen, a business accelerator for female entrepreneurs.  She currently leads Ascend 2020, a technology startup and small business pre-accelerator for minority and female founders.  Additionally, Tanya serves on the Board of Directors for Kate's Club, a non-profit organization that empowers children that have experienced the death of a parent or sibling.  This organization and all the children they help hold a special place in her heart as she also experienced loss at an early age, losing her mother at the age of 12.Tanya appears on the show The Real Housewives of Atlanta. Tanya lives in Atlanta, Georgia, with her fiancé Dr. Paul Judge, a technology entrepreneur and investor. She was born in Toronto, Canada and her parents are from Ghana and England.  Tanya earned a Bachelor of Science in Genetics and Cell Biology from McGill University and a Bachelor of Science in Nursing from The University of Toronto. She has practiced nursing for over a decade in some of the top oncology hospitals in Toronto, New York and Atlanta including Princess Margaret Hospital, Northside Hospital, and New York Presbyterian.  She is a fashionista, an avid runner, workout queen, spin-cyclist, traveler, foodie and bibliophile.#RHOA #TanyaSam #SippinTheTea #ArianeAndrew #MattDillon

Twenty-plus years into her successful corporate career, Claudia Harvey began her first independent venture with Dig It Apparel® Inc. (www.digitapparel.com). Dig It® struck a deal with Kevin O’Leary, famous venture capitalist of CBC Canada’s Dragons’ Den and NBC’s Shark Tank. The resulting deal opened the door to launching and investing in other businesses and making a quantifiable difference in the lives of others.As a Founding Partner of BG Wealth Group Inc., BG Investment Holdings Inc., and BG Marketing Authority, Claudia and her team help others emulate her success, grow their businesses, and expand their wealth. In 2019, Claudia was awarded the Top Female Business Leader Award from New York’s International Association of Top Professionals. She also joined other outstanding influencers – such as Oprah Winfrey and Melinda Gates – as a contributing author of America’s Leading Ladies.As she balanced raising a family of 3 and creating her own businesses, Claudia became an international keynote speaker and shared events with notables such as Tony Robbins, Mark Victor Hansen, Bill Walsh, Jim Treliving, Pitbull, and many more.Aside from her successful career, Claudia believes in the power of paying it forward and helping organizations dedicated to empowering women and youth. She sits on the international Advisory Board of Sonas.org and created the BG Scholarship Fund, which provides under-privileged children with a post- secondary education that will help them realize and achieve their full potential. Never forgetting her Canadian roots, Claudia is also a member of the Foundation Board of Princess Margaret Hospital, one of the five most renown cancer research hospitals in the world. https://parkbench.com/blog/bg-wealth-group-business-services-mill-pond-richmond-hill-claudia-harvey

Today we are joined by Dr Rob Hamilton, Urologist at Princess Margaret Hospital in Toronto, and world-leading testis cancer specialist. Rob has been running a randomised trial of telehealth surveillance for testis cancer patients so has some great insights and advice for the rest of us. We also discuss his interest in testis cancer biomarkers and robotic surgery for retroperitoneal testicular cancer. Declan Murphy and Renu Eapen are joined again by Dr Ben Tran, Medical Oncologist at Peter Mac who knows Rob from his time doing a Fellowship at Princess Margaret. 

China’s National Health Commission said there was a total of 74,185 confirmed cases as of Feb. 18, and 2,004 people have died so far. South Korea confirmed 15 additional cases, bringing the total number of affected patients to 46. A second person, a 70-year-old man, has died in Hong Kong from the infection, a spokeswoman at the Princess Margaret Hospital told CNBC. --- Support this podcast: https://anchor.fm/newscast-africa/support Learn more about your ad choices. Visit megaphone.fm/adchoices

In this podcast lecture, Dr Anne Halbert, Consultant Dermatologist at Princess Margaret Hospital, will provide practical advice on the prevention and management of atopic dermatitis in babies and children. The risks and benefits of topical corticosteroids and calcineurin receptor antagonists will be covered in detail, along with ways in which to maximise benefit.

Capital Ideas Media publisher Mark Bunting talks to Aras Azadian, the CEO of newly-public Avicanna (TSX:AVCN), a science-based, low-cost cannabis company with an impressive list of partners from Johnson & Johnson to Princess Margaret Hospital.

Dr Anne Halbert, a Consultant Dermatologist at Princess Margaret Hospital for Children, provides practical advice on the prevention and management of atopic dermatitis in babies and children, including the science of treatment and the art of inspiring children and parents to comply. She also discusses the risks and benefits of topical corticosteroids and calcineurin receptor antagonists, and how to maximise benefit.

On our first podcast, Dr. Paul Wheatley-Price, Medical Oncologist at The Ottawa Hospital and President of Lung Cancer Canada, speaks to Dr. Natasha Leighl, Medical Oncologist at Princess Margaret Hospital and Dr. David Gandara of UC Davis, Sacramento. For more information on lung cancer visit www.lungcancercanada.ca

In this episode of my Authentic Leadership Podcast, Gabrielle had the pleasure of chatting with Shelley Park. She is the CEO of Australian Red Cross Blood Services. Not many of us can claim that our job is saving lives, but Shelley and her team can. Prior to joining the Blood Service, Shelley was Chief Executive of Monash Health, which provides healthcare services to over a million people in Melbourne. Her previous positions have also included Executive Director of Jessie McPherson Private Hospital, General Manager of Medical and Surgical Services at Christchurch Hospital (New Zealand), and General Manager at The Princess Margaret Hospital in Canterbury, New Zealand. Her 20 years of business experience at a senior level has been supplemented by formal studies including a Master of Science in Management from Ashridge Business School (UK) and a Bachelor of Arts in Business Administration and Management from Massey University (New Zealand). Have a listen to find out what this amazing leader thinks of authenticity, diversity and gardening.

THOMAS BAKER ORATION "Striving for Excellence in Health Care" Professor Fiona Wood has been a burns surgeon and researcher for the past 20 years and is Director of the Burns Service of Western Australia (BSWA). She is a Consultant Plastic Surgeon at Fiona Stanley Hospital (previously at Royal Perth Hospital) and Princess Margaret Hospital for Children, co-founder of the first skin cell laboratory in WA, Winthrop Professor in the School of Surgery at The University of Western Australia, and co-founder of the Fiona Wood Foundation (formerly The McComb Foundation). Professor Fiona Wood's dedication to improving outcomes for burns patients and expanding the knowledge of wound healing began in 1991 when she became trained as West Australia's first female plastic surgeon. Professor Wood's ability to lead a team and direct innovation for future clinical care was recognised as she quickly became a leader in her field becoming Director of the Burns Service of Western Australia at an early point in her career. In this position Professor Wood has led the Burns Service of Western Australia to be recognised internationally as a leader in burns care. Professor Wood's greatest contribution and enduring legacy is her work pioneering the innovative ‘spray-on skin' technique (Recell), which greatly reduces permanent scarring in burns victims. Professor Wood patented her method in 1993 and today the technique is used worldwide. In October 2002, Fiona was propelled into the media spotlight when the largest proportion of survivors from the 2002 Bali bombings arrived at Royal Perth Hospital. She led a team working to save 28 patients suffering from between 2 and 92 per cent body burns, deadly infections and delayed shock. Fiona was named a Member of the Order of Australia (AM) in 2003. In 2005 she won the Western Australia Citizen of the Year award for her contribution to Medicine in the field of burns research. That same year her contribution to burns care was recognised through Australia's highest accolade when she was named Australian of the Year for 2005 by Australian Prime Minister John Howard at a ceremony in Canberra to mark Australia Day. She is an Australian Living Treasure. Professor Wood was voted the most-trusted Australian in a Reader's Digest poll for six successive years from 2005 to 2010. Fiona is married to fellow surgeon Tony Kierath and is mother to four boys and two girls.

“I'm sick and tired of the things you never get tired of…so that's why I decorate my house the way I do”     Every community has characters.  Evi Ferrier is one of Perth's.   Her home, in the swanky suburb of Mosman, is mosaicked from top to bottom  - a riot of eye-catching  colour in a sea of boring good taste.  Her free spirit and sense of fun pervades everything she does and she's a strong supporter of the arts as well as being an artist herself. Although she'd shown aptitude for art at school, it wasn't until she was married with children that Evi attended the Claremont School of Art and fell in love with mosaicking.    In a sense, it was borne of Evi's loathing of waste, that her childrens' craft activities as well as broken crockery and mirrors were not destined for the rubbish bin, but for adorning her home.  For Evi, the mosaicking is her “gardening” and even now she'd been in that house for 30 years , there's an ongoing project.   Recently her bowerbird tendencies prompted a “sculpture park” on an empty block across the road from her home – an open “house” with rooms and furniture that grew up out of  junk left out for roadside collection. The whole community got involved in the fun and when it was time to end it – she held a party there.   Friends say she's the best kind of friend herself, generous and caring, and this sense of community extends to volunteer work.  Evi has volunteered in Africa three times inspired by Gemma Sisia, the Australian woman who has set up the School of St Jude in Tanzania and Evi has also helped with children with eating disorders at Princess Margaret Hospital for Children and with disabled children at Rocky Bay.     Now in her early 70's Evi energetically pursues numerous interests ranging from dragon boating to knitting to tap dancing and continues to delight all who come across her.   Thanks a million to Evi for sharing some of her stories with us and allowing us to photograph her delightful home. Recorded at Evi Ferrier's home in Mosman, Western Australia Mixed by Adrian Sardi Rare Air podcast © Meri Fatin Theme music Les Jeunes Pousses by Françoiz Breût Production music Another Day by Ketsa ( Free Music Archive)

Set in and around the Princess Margaret Hospital, the story of Alan and Moira exposes the harsh realities of the solitude and fears that accompany cancer treatment with brutal honesty and wry humour. Pettle’s writing comes from a place of awful familiarity, as he explains in his forward, "It’s July 15, 1995, and I’m back in the hospital - radioactive iodine therapy, cancer treatment’s answer to solitary confinement. Why did I write this play? I wrote it to survive days like this. [...] I wrote it not only for those who have passed on to other journeys, but for all those who remain in Therac corridors everywhere. People that are not just statistics in flimsy pamphlets or black numbers on manila envelopes, but individuals with brilliant minds and raging spirits, with awe-inspiring courage and beautiful children."It was the personal connection to this story that brought this production into existence and provides the motivation to engage in the realities of the content beyond the story-telling. As well as donating a percentage of both the ticket proceeds and additional fundraising efforts to the Princess Margaret Cancer Foundation and Gilda’s Club Greater Toronto , the production is coordinating with several organizations to provide talk-back opportunities and other activities in support of the individuals and families fighting the disease both known and unknown to us.Cass Van Wyck: Twitter: @classvanwyck Instagram: classvanwyckJessie Fraser: Instagram: slackbabyChristopher Lewis:http://www.majorcallisto.com/ Instagram: majorcallistoTickets: https://www.brownpapertickets.com/event/3373355 Facebook: https://www.facebook.com/events/1886254528331793/

Dr. Jeremy Freeman was born in Hamilton, Ontario and grew up in Toronto. He attended medical school at the University of Toronto, graduating with highest honours. He completed his otolaryngology residency at the University of Toronto. After receiving his Fellowship from the Royal College of Surgeons of Canada in 1978, he spent two further years of advanced training, one as a Gordon Richards Fellow at the Princess Margaret Hospital in Toronto in Radiation and Medical Oncology and a second year as a McLaughlin Fellow, training in Head and Neck Oncology at the Royal Marsden Hospital in London, UK. He was the first fellow of the Advanced Training Council sponsored by the two head and neck societies. A Full Professor, he occupies the Temmy Latner/Dynacare Chair in Head and Neck Oncology at the University of Toronto, Faculty of Medicine. He is former Otolaryngologist-in-Chief at the Mount Sinai Hospital stepping down after fulfilling his 10 year appointment. He has an active practice focusing on head and neck oncology with a primary interest in endocrine surgery of the head and neck. He has given over 500 scholarly presentations, has been invited as a visiting professor and surgeon internationally, and has published over 280 articles in the scientific literature. He has been involved in a number of administrative roles in the American Head and Neck Society and is also on the editorial board of a number of high impact journals focusing on head and neck oncology. He has recently been appointed to the National Institute of Health (in Washington DC) task force on the management of thyroid cancer. He is the Director of the University of Toronto Head and Neck Oncology Fellowship, considered to be one of the top three such fellowships in North America. He was the program chair and congress chair of the First and Second World Congresses on Thyroid Cancer held in 2009 and 2013 in Toronto. He was the Keynote speaker at the Congress held in Boston in 2017. He has been invited worldwide to deliver keynotes in the management of thyroid malignancies. In this episode the following topics are discussed: Cost of thyroid surgery in varies depending on jurisdiction Surgery and active surveillance is a fixed cost Costs after surgery TG tests, ultrasound, thyroid hormone costs Contrary to some proponents, surgery is not more cost effective than active surveillance Hypo parathyroidism leads to daily doses of calcium and vitamin D If there is RLN damage, then there could be more surgery and voice therapy There are more costs than solely the surgical fee Levothyroxine costs Ramifications of degree of thyroid cancer Thyroid cancer is a low risk of death Many people die with thyroid cancer but don’t die from it Possibility versus probability Emotional expense of malignancy and being labeled survivor Lead a normal life or the survivor label Lifetime cost of thryoidectomy Medical costs and cost of travel, time of work, baby-sitters, and all expenses that go into managing thryoidectomy for ancillary items How long can someone live without thyroid replacement hormone post thyroidectomy? Quality of life post thyroidectomy Psychological wellbeing Do not do a FNA for nodule under 1 cm NOTES Dr. Jeremy Freeman Jeremy Freeman's scientific contributions LinkedIn  

Dr. Angela Alessandri shares her journey as consultant clinical paediatric haematologist/oncologist at Princess Margaret Hospital. Angela talks very openly about her personal journey to becoming a doctor, connecting and being present with humanity in the most challenging of circumstances and the process of breaking the news of a cancer diagnosis to parents. She also shares the personal impact and toll caused by the role and how this has reshaped her future focus and views on how to treat patients. This is a very confronting conversation in places, but worth the journey to reflect upon our own mortality so we can live the most fullest life. 

The fourth interview from the ANZICS-CTG podcast series from Noosa 2016 is with Dr Simon Erickson.  Simon is a senior Intensivist from the Princess Margaret Hospital for Children in Perth, Australia, and is part of a proposed study of Nitric Oxide and its effect on Paediatric post operative cardiac surgical population.

On this edition of the Zoomer Week in Review, filmmaker Simcha Jacobovici stops by to talk about his new documentary The Jesus Discovery. Libby visits Princess Margaret Hospital and learns about the new gene profiling lab and IMPACT trial. Billie Holiday's birthday is celebrated with a look back at the singer's life and songs.

On this Edition of The Zoomer Week in Review:This Monday marked 100 years since Austria-Hungary officially declared war on Serbia, putting the first world war in motion. It was one of the largest and bloodiest military conflicts in human history. Libby is joined by historian Margaret Macmillan to examine the unique series of events that lead up the war, and how it impacted the countries involved.And, this week Toronto's Ursula May celebrated a very joyous anniversary - 50 years of being cancer free. The 90 year old may just be the longest breast cancer survivor to be treated at Princess Margaret Hospital. We'll talk to Ursula what it was like to be diagnosed with Cancer at a time when the disease was still largely a mystery to the medical community - and how far treatments options have come since then!

On this Edition of The Zoomer Week in Review:This Monday marked 100 years since Austria-Hungary officially declared war on Serbia, putting the first world war in motion. It was one of the largest and bloodiest military conflicts in human history. Libby is joined by historian Margaret Macmillan to examine the unique series of events that lead up the war, and how it impacted the countries involved.And, this week Toronto's Ursula May celebrated a very joyous anniversary - 50 years of being cancer free. The 90 year old may just be the longest breast cancer survivor to be treated at Princess Margaret Hospital. We'll talk to Ursula what it was like to be diagnosed with Cancer at a time when the disease was still largely a mystery to the medical community - and how far treatments options have come since then!

On this episode I have Rob Dyer as my guest. Rob is the founder of Skate4Cancer and has completed 4 cross country skateboarding marathons in his life. He's skateboarded from Los Angeles to Toronto, across Canada, across France and across New Zealand. Rob does this all in the name of cancer prevention and awareness. Throughout his days, he's partnered with organizations like Princess Margaret Hospital and Wellspring to fight back against cancer. In high school, Rob lost his mom, two grandmas and a friend to cancer in a relatively short period of time. This pain inspired him to take action. "The initial idea came from people in my life going through cancer. So often when we think about diseases like AIDs and cancer, and we feel they are larger than us."Over the last 12 years Rob has been able to create a community for people battling with cancer and lending support to the friends and families of cancer victims. He's inspired thousands of people and supported many more along the way.Currently as you read this, Rob is biking from Toronto to New Orleans to raise money for Wellspring, an organization he works with dearly and proudly supports. Rob has reached 95% of his fundraising goal and could use our help to surpass it! Today is the last day he will be accepting donations.We start off the podcast by talking about what inspired Skate4Cancer. The first 25 minutes is a discussion about his skateboarding marathons and the lessons he's learned from them. At the 25 minute mark, we talk about the value of giving back to other human beings and if Rob will do Skate4Cancer for the rest of his life. We wrap up the podcast by talking about Wellspring and his current project, the bike ride from Toronto to New Orleans.Notable Sections in the Podcast2:10 - Where Skate4Cancer began. Rob didn't want cancer, a disease that so many people feel powerless about, to have power over his life. So he did what he knew best and started skateboarding. 11:50 - "We put our dreams into small boxes and it we don't make it we say it's a failure."15:45 - Rob's view on overcoming obstacles and how there is no one set method to overcome all the obstacles we will face in life. Each one is unique and will come with its own set of difficulties that we will have to courageously face dead on.27:00 - Rob on giving... "It's an addictive thing. It's something as humans that is built into us. It's what makes us human is being able to affect the lives of others... it's what we're meant to do."Rob can be found on Instagram @ robdyerS4C 

“I’m sick and tired of the things you never get tired of…so that’s why I decorate my house the way I do” Every community has characters. Evi Ferrier is one of Perth’s. Her home, in the swanky suburb of Mosman, is mosaicked from top to bottom - a riot of eye-catching colour in a sea of boring good taste. Her free spirit and sense of fun pervades everything she does and she’s a strong supporter of the arts as well as being an artist herself. Although she’d shown aptitude for art at school, it wasn’t until she was married with children that she attended the Claremont School of Art and fell in love with mosaicking. In a sense, it was borne of Evi’s loathing of waste, that her children's craft activities as well as broken crockery and mirrors were not destined for the rubbish bin, but for adorning her home. For Evi, the mosaicking is her “gardening” and even now she’d been in that house for 30 years , there’s an ongoing project. Recently her bowerbird tendencies prompted a “sculpture park” on an empty block across the road from her home – an open “house” with rooms and furniture that grew up out of junk left out for roadside collection. The whole community got involved in the fun and when it was time to end it – she held a party there. Friends say she’s the best kind of friend herself, generous and caring, and this sense of community extends to volunteer work. Evi has volunteered in Africa three times inspired by Gemma Sisia, the Australian woman who has set up the School of St Jude in Tanzania and Evi has also helped with children with eating disorders at Princess Margaret Hospital for Children and with disabled children at Rocky Bay. Now in her early 70’s Evi energetically pursues numerous interests ranging from dragon boating to knitting to tap dancing and continues to delight all who come across her. Thanks a million to Evi for sharing some of her stories with us and allowing us to photograph her delightful home.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes new targets for squamous cell non-small cell lung cancer and anti-PD1 immunotherapy that has emerged as one of the most promising new developments in lung cancer from 2012.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes new targets for squamous cell non-small cell lung cancer and anti-PD1 immunotherapy that has emerged as one of the most promising new developments in lung cancer from 2012.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes new targets for squamous cell non-small cell lung cancer and anti-PD1 immunotherapy that has emerged as one of the most promising new developments in lung cancer from 2012.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes new targets for squamous cell non-small cell lung cancer and anti-PD1 immunotherapy that has emerged as one of the most promising new developments in lung cancer from 2012.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes new targets for squamous cell non-small cell lung cancer and anti-PD1 immunotherapy that has emerged as one of the most promising new developments in lung cancer from 2012.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes new targets for squamous cell non-small cell lung cancer and anti-PD1 immunotherapy that has emerged as one of the most promising new developments in lung cancer from 2012.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes emerging data on the efficacy of ALK inhibitors for patients with advanced NSCLC that harbors an ALK or ROS1 rearrangement.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes emerging data on the efficacy of ALK inhibitors for patients with advanced NSCLC that harbors an ALK or ROS1 rearrangement.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes emerging data on the efficacy of ALK inhibitors for patients with advanced NSCLC that harbors an ALK or ROS1 rearrangement.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes emerging data on the efficacy of ALK inhibitors for patients with advanced NSCLC that harbors an ALK or ROS1 rearrangement.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes emerging data on the efficacy of ALK inhibitors for patients with advanced NSCLC that harbors an ALK or ROS1 rearrangement.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes emerging data on the efficacy of ALK inhibitors for patients with advanced NSCLC that harbors an ALK or ROS1 rearrangement.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.

In the third and final part of our discussion of stem cells, we complete our conversation between Professor Derek van der Kooy and Claire Moffatt from the most recent Stem Cell Talks at the University of Toronto. Professor Ian Rogers from the Lunenfeld Institute at Princess Margaret Hospital returns to answer even more student questions from Stem Cell Talks. (music by Broken Social Scene) Be sure to send in any questions you'd like to have answered on the podcast!

We continue our discussion of stem cells with the second part of our conversation between Professor Derek van der Kooy and Claire Moffatt from the most recent Stem Cell Talks at the University of Toronto. Professor Ian Rogers from the Lunenfeld Institute at Princess Margaret Hospital joins us to answer student questions from Stem Cell Talks. (music by Grimes)

Charissa Cordon talks to ecancer at ICCN 17 in Prague about the development of the Oncologic Emergencies course and the importance of understanding adult learning principles. Originally offered as a two-day workshop, the course built on foundational knowledge where newly hired nurses, as well many experienced nurses, learnt how to identity risk factors not normally seen in their specific field. In total eleven different emergency areas were discussed. Because many nurses wanted to attend but could not due to various limitations such as nursing shift schedules, staffing issues, presenter availability and physical space , the workshop was developed into an educational module that was made available online, thus making it more accessible for nurses. Ms Cordon also talks about importance of elearning formats and accessibility, as well as her presentation on adult learning principles for designing the course.

The use of metformin in men with prostate cancer before prostatectomy helped to reduce certain metabolic parameters and slow the growth rate of the cancer, according to the results of a phase II study. Dr Joshua, from the Princess Margaret Hospital, University Health Network in Toronto, presented the data at the AACR Annual Meeting 2012